<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"><html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="X-UA-Compatible" content="IE=edge" /><link rel="shortcut icon" href="dailymed/images/favicon.ico" /><meta name="ROBOTS" content="NOFOLLOW" /><script type="text/javascript" src="/dailymed/scripts/1.10.2/jquery-1.10.2.min.js"></script><script type="text/javascript" src="/dailymed/scripts/jquery-ui/jquery-ui.min.js"></script><script type="text/javascript">	var jQuery_1_10_2 = $.noConflict();</script><link rel="stylesheet"   href="dailymed/scripts/jquery-ui/smoothness/jquery-ui.min.css" type="text/css" /><link rel="stylesheet"   href="dailymed/styles/base.css?v=1.2" type="text/css"  /><script src="/dailymed/scripts/drop_down.js" type="text/javascript"></script><script src="/dailymed/scripts/shared.js" type="text/javascript"></script><!--[if IE]><link rel="stylesheet" type="text/css" href="dailymed/styles/ie-hacks.css" /><![endif]--><script type="text/javascript" src="/dailymed/scripts/1.3.2/jquery.js"></script> <script type="text/javascript" src="/dailymed/scripts/autocomplete/jquery.autocomplete.js"></script><script type="text/javascript">	$(document).ready(function(){				// check to see if autocomplete plugin has been loaded by looking for existance of "autocomplete" function in jQuery object		if( $.fn.autocomplete ) {  			// THE PLUGIN HAS BEEN LOADED!			//alert(" autocomplete is already loaded! great! ");		}		else {			// reinsert the script tag into the head to load the autocomplete plugin						//alert(" we need to load in autocomplete..." );			$("head").append('<script type="text/javascript" src="/dailymed/scripts/autocomplete/jquery.autocomplete.js" />');			}				// actually activate autocomplete		$("#startswith").autocomplete("/dailymed/autocomplete.cfm?key=search",{			width: 275,			selectFirst: false,			cacheLength:1,			max:200,			matchSubset:false,			delay:300,			minChars:3		});	});   </script>    <link rel="stylesheet"   href="dailymed/scripts/autocomplete/jquery.autocomplete.css" type="text/css" />  <noscript>Your browser does not support JavaScript!</noscript>		<title>PLAVIX (CLOPIDOGREL BISULFATE) TABLET, FILM COATED [REBEL DISTRIBUTORS CORP]</title><link rel="alternate" type="application/rss+xml" href="dailymed/labelrss.cfm?setid=1086a7b4-b89b-4bee-8120-5f752626c046"title="RSS Feed for PLAVIX (CLOPIDOGREL BISULFATE) TABLET, FILM COATED [REBEL DISTRIBUTORS CORP] Label"/><link rel="bookmark" href="lookup.cfm?setid=1086a7b4-b89b-4bee-8120-5f752626c046" title="PLAVIX (CLOPIDOGREL BISULFATE) TABLET, FILM COATED [REBEL DISTRIBUTORS CORP]" /><link rel="stylesheet" type="text/css" href="fdastyles/spl.css" /><link rel="stylesheet" type="text/css" href="styles/layouts/slidingdoors.css" /><link rel="stylesheet" href="styles/colorbox.css" type="text/css" media="screen" /><script language="javascript" type="text/javascript" src="scripts/jquery.colorbox-min.js"></script><script type="text/javascript" src="scripts/autocomplete/lib/jquery.bgiframe.min.js"></script><script type="text/javascript" src="scripts/autocomplete/lib/jquery.dimensions.js"></script></head><body>	<div id="controls"><ul>    	<li><a class="skipicon1" href="#druglabelcontent" title="Skip to DrugLabel content paragraph">Skip to DrugLabel content</a></li>	<li><a class="skipicon2" href="#dmsections" title="Skip to DrugLabel sections paragraph">Skip to DrugLabel sections</a></li>   </ul></div>  <div id="dailymedbanner">  		<div id="brandimage">        <img src="images/DM_LOGO_HEADER.png" alt="DailyMed Logo Header image" />        </div>        <div id="top">          <h1>Daily            <span>Med</span>          </h1>          <h2>            <span>Current </span>            <span>Medication </span>            <span>Information</span>          </h2>        </div>  </div><div id="actions">	<div id="options">		<h2>Options</h2>		<ul id="dmnav">	      		<li>					<a 	title=" Link to DailyMed Home "						href='/dailymed/about.cfm'						id="home">Home</a>				</li>	      		<li>					<a 	title=" Link to E-mail Label Information "						href="dailymed/emailWebLink.cfm"						id="email">E-mail Label Information</a>				</li>				<li><a 	class="rightarrow"						href="#"						title="Links to download options">Downloads</a>					<ul>						<li>							<a	title=" Link opens new window to download all drug labels "								href="dailymed/downloadLabels.cfm">Download All Drug Labels</a>						</li>                        <li>                        	<a	title=" Link opens new window to download all indexing files"                             	href="dailymed/downloadIndexing.cfm">Download All Indexing Files</a>                        </li>                        <li>                        	<a	title=" Link opens new window to download all mapping files"                             	href="dailymed/downloadMappingFiles.cfm">Download All Mapping Files</a>                        </li>												<li>							<a	title=" Link opens new window to download this label (XML) "								href="dailymed/getFile.cfm?setid=1086a7b4-b89b-4bee-8120-5f752626c046&amp;type=zip&amp;name=PLAVIX">Download this Label(XML)</a>						</li>						                        					</ul>				</li>								<li><a 	title="SPL History"						href="dailymed/splshistory.cfm?setid=1086a7b4-b89b-4bee-8120-5f752626c046"						id="splhistory">SPL History </a>				</li>				<li><a 	title="Link to Print this Label"						href="dailymed/fda/fdaDrugXsl.cfm?setid=1086a7b4-b89b-4bee-8120-5f752626c046&amp;type=display"						id="printitem"						target="_blank"> Print this Label </a>				</li>                <li>                				                    <a	title="Download PDF of this Label"                             href="dailymed/getFile.cfm?setid=1086a7b4-b89b-4bee-8120-5f752626c046&amp;type=pdf&amp;name=1086a7b4-b89b-4bee-8120-5f752626c046"                            id="downloadpdf"> Download this Label (PDF)</a>                                                               </li>        					      	    <li>						<a	title=" Notify of Updates "						href="dailymed/rsshome.cfm?setid=1086a7b4-b89b-4bee-8120-5f752626c046"						id="rss">Notify of Updates</a>				</li>	      		<li>					<a	title=" Contact Us "						href="dailymed/contactUs.cfm"						id="contact">Contact Us</a>				</li>                <li>					<a	title=" Help "						href="dailymed/help.cfm"						id="help">Help</a>				</li>                <li>					<a	title=" Web Services "						href="dailymed/help.cfm#webservices"						id="help">Web Services</a>				</li>                <li class="new-option">                	<a	title=" Browse Drug Classes "                    	href="dailymed/browseClasses.cfm"                        id="browse">Browse Drug Classes                    </a>                                    </li>				<li><h2>Additional Resources</h2></li>                <li>                	<a 	class="rightarrow"                		href="#"	                    title="Links to DailyMed presentations and related material">DailyMed Presentations and Related Material</a>                	<ul>                    	<li>                        	<a	href="http://videocast.nih.gov/Summary.asp?File=18134"                            	title="SPL/DailyMed Jamboree Workshop Videocast">SPL/DailyMed Jamboree Workshop Videocast</a>                        </li>                        <li>                        	<a	href="http://www.nlm.nih.gov/mesh/spl_workshop.html"                            	title="SPL/DailyMed Jamboree Workshop Slides">SPL/DailyMed Jamboree Workshop Slides</a>                        </li>                    </ul>                </li>                <li>                    <a	href="http://www.fda.gov/oc/datacouncil/spl.html"                        title="Link opens in a new window for FDA SPL Resources"                        target="FDA">FDA Structured Product Labeling Resources                     </a>                </li>				<li>					<a	id="splimagesspec"						href="dailymed/splimagesspec.cfm"						target="SPLIMAGESPEC"						title="SPLIMAGE Specifications">SPLIMAGE Specification Version 3.0.2  </a>				</li>				<li>					<a	id="report"						href="http://www.fda.gov/medwatch/how.htm"						target="FDA"						title="FDA Page to Report Adverse Event">Report Adverse Event</a>				</li>																				    <li><a href="http://www.nlm.nih.gov/search/medlineplus?query=clopidogrel" title="Link opens new window to MedlinePlus Information" target="medlinePlus">MedlinePlus Information</a></li>			    <li><a href="http://www.clinicaltrials.gov/ct/search?submit=Search&amp;term=clopidogrel" title="Link opens new window to Find Clinical Trials" target="clinicalTrials">Find Clinical Trials</a></li>				<li><a href="http://www.drugbank.ca/search/search?query=APRD00444" title="Link opens new window to University of Alberta DrugBank" target="drugBank">Biochemical Data Summary</a></li>			    <li><a href="#" class="rightarrow" title="Links to Search PubMed Articles">Search PubMed Articles</a>				  <ul>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=clopidogrel[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=clopidogrel/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=clopidogrel/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=clopidogrel/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=clopidogrel[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a></li>				  </ul>			    </li>				<li>					<a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+lact:@na+clopidogrel" target="toxnet" title="Link opens new window for Presence in Breast Milk">Presence in Breast Milk</a>								</li>                <script> $(function() {			jQuery_1_10_2( "#dialog-confirm" ).dialog({			  resizable: false,			  modal: true,			  autoOpen: false,			  position: {				my: "center",				at: "center",				of: $("body"),				within: $("body")			  }			});					jQuery_1_10_2( ".disclaimer-link" ).click( function(event){				event.preventDefault();				jQuery_1_10_2( "#dialog-confirm" ).dialog( "option", "buttons", 					[						{							text: "Continue", 							click: function() {								jQuery_1_10_2( this ).dialog( "close" );								$( "a.rximage" )[0].click();							}						},						{							text: "Cancel", 							click: function() {								jQuery_1_10_2( this ).dialog( "close" );							}						}					]				);								jQuery_1_10_2( "#dialog-confirm" ).dialog( "open" );			});						$( ".rximage" ).colorbox({				rel:'rximage',				maxHeight:'100%',				maxWidth:'100%'			});		});</script><div id="dialog-confirm" title="Disclaimer" style="display:none;">  <p><span class="ui-icon ui-icon-alert" style="float: left;"></span>&nbsp;<strong>Disclaimer:</strong> These images are provided by the National Library of Medicine (NLM) and are not part of the official label.</p> </div>    	    	     </ul>		 		 	<div id="mdswitch">									<a  href="dailymed/drugInfo.cfm?id=34869&amp;dictionary=on"						title="Turn Dictionary Words On">						<img src="/dailymed/images/dictionaryon.jpg" alt="Turn Dictionary Words On"/>					</a>							</div>				</div>							<style type="text/css">		html body {		min-width:1024px;		}        .smallimage {            border: 1px solid ##ACBECE;        }</style>						    	    																																																								    	    	                             		       	                                           <script>	$(function() {		$( '.splimage' ).colorbox({			rel:'splimage',			maxHeight:'100%',			maxWidth:'100%'		});	});</script>		            </div><div id="content"><div id="searchpane"><div id="search"><form action="/dailymed/search.cfm" name="searchform"><div class="divtable">    <div class="divtr">            <div class="divtd">Search :</div>            <div class="divtd">            	<label for="startswith" class="invisibletag">Enter a drug Name to search</label>                <input style="width:95%;"                type="text"                 id="startswith"                 name="startswith"                 title="enter a drug name to search"                  onclick="javascript:resetme()" /> &nbsp;                       </div>            <div class="divtd">              	<label for="go" class="invisibletag">Go</label>                <input type="image"                 src="/dailymed/images/goButton.gif"                 alt="Click this button to start your drug name search"                 title="Click this button to start your drug name search"                 id="go"/> &nbsp;            </div>            <div class="divtd80">            	<a href="dailymed/advancedSearch.cfm">Advanced Search</a>            </div>    </div>    <div class="divtr">    		<div class="divtd85">Limits:</div>            <div class="divtd85">                <input  class="searchoptions"  type="radio" name="searchdb" value="drugname" id="name-radio" title="Drug Name" />                <label for="name-radio" class="searchoptions">Drug Name</label>                <input  class="searchoptions"  type="radio" name="searchdb" value="ndc" id="ndc-radio" title="NDC Code" />               	<label for="ndc-radio" class="searchoptions">NDC Code</label>                <input  class="searchoptions"  type="radio" name="searchdb" value="drugclass" id="class-radio" title="Drug Class" />               	<label for="class-radio" class="searchoptions">Drug Class</label>                <input  class="searchoptions"  type="radio" name="searchdb" value="setid" id="setid-radio" title="SETID" />               	<label  for="setid-radio" class="searchoptions">SetId</label>            </div>    </div>    <div class="divtr">            <div class="divtd85">Label Type:</div>            <div class="divtd85" style="float:left;">                <input class="searchoptions" type="radio" name="labeltype" value="human" id="human-radio" title="Human Drugs" />               	<label for="human-radio" class="searchoptions">Human Drugs</label>                <input class="searchoptions" type="radio" name="labeltype" value="animal" id="animal-radio" title="Animal Drugs" />               	<label for="animal-radio" class="searchoptions">Animal Drugs</label>            </div>    </div>          </div></form></div></div>		<div id="rxnormlist">		<h3>RxNorm Names</h3>								<ul style="maring:0px; padding:0px;">				<li id="item1" style="padding:1px; margin:1px;">					  						<a 	id="viewrxnorm"							href="rxnormdata.cfm?setid=1086a7b4-b89b-4bee-8120-5f752626c046"							onclick="rxnormpopup(this.href);return false;"							target="rxnorm" title="Link to Review RxNorm Normal Forms" >							<img src="images/closed.gif"								 alt="Icon attached Review or Hide All RxNorm Normal Forms Link"								 id="img_item1"								 border="0"								 style="clear:none;float:left">Review RxNorm Normal Forms</a>					  			  	</li>			 </ul>				</div>	<p class="DocumentTitle"><strong>PLAVIX				(clopidogrel bisulfate) 			tablet, film coated</strong><br> [Rebel Distributors Corp] 	</p><br><div class="permalink">	<h3><strong>Permanent Link: </strong></h3><span><a href="lookup.cfm?setid=1086a7b4-b89b-4bee-8120-5f752626c046">http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1086a7b4-b89b-4bee-8120-5f752626c046 </a><span></div><div id="nlmdrugstatus"><table border="4" width="100%" style="border: 1px solid rgb(142, 1, 10); padding: 0pt; float: right; margin-bottom: 0.75em; margin-top: 0.75em; position: relative; right: 0pt;"><thead align="left" bgcolor="#F6F6F6" style="color:#8e010a; font-size:1.2em"><tr><th scope="col">	<a class="anchor1" href="http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162063.htm" target="fda"onclick="fdapopup(this.href);return false;" title="Document Type including Content of Labeling Type">Category</a></th><th scope="col">	<a class="anchor1" href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071816.htm" target="fda" onclick="fdapopup(this.href);return false;" title="SPL DEA Schedule">DEA Schedule</a></th><th scope="col"><a class="anchor1" href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071826.htm" target="fda" onclick="fdapopup(this.href);return false;" title="Marketing Category">Marketing Status</a></th></tr></thead><tbody><tr><td scope="row"><strong>HUMAN PRESCRIPTION DRUG LABEL</strong></td><td scope="row"><strong></strong></td><td scope="row"><strong>New Drug Application</strong></td></tr></tbody></table><div id="disclaimer" >		</div></div><div id="dmsectionsfieldset"><fieldset><legend>Drug Label Sections</legend><div id="dmsections"><ul><li><a title="Description" href="#nlm34089-3" class="nlmlinktrue">Description</a></li><li><a title="Clinical Pharmacology" href="#nlm34090-1" class="nlmlinktrue">Clinical Pharmacology</a></li><li><a title="Indications &amp; Usage" href="#nlm34067-9" class="nlmlinktrue">Indications &amp; Usage</a></li><li><a title="Contraindications" href="#nlm34070-3" class="nlmlinktrue">Contraindications</a></li><li><a title="Warnings" href="#nlm43685-7" class="nlmlinktrue">Warnings</a></li><li><a title="Precautions" href="#nlm43685-7" class="nlmlinktrue">Precautions</a></li><li><a title="Adverse Reactions" href="#nlm34084-4" class="nlmlinktrue">Adverse Reactions</a></li><li><a title="Overdosage" href="#nlm34088-5" class="nlmlinktrue">Overdosage</a></li><li><a title="Dosage &amp; Administration" href="#nlm34068-7" class="nlmlinktrue">Dosage &amp; Administration</a></li><li><a title="How Supplied" href="#nlm34069-5" class="nlmlinktrue">How Supplied</a></li><li><a title="Patient Counseling Information" href="#nlm34076-0" class="nlmlinktrue">Patient Counseling Information</a></li><li><a title="Supplemental Patient Material" href="#nlm38056-8" class="nlmlinkfalse">Supplemental Patient Material</a></li><li><a title="Boxed Warning" href="#nlm34066-1" class="nlmlinktrue">Boxed Warning</a></li><li><a title="Patient Package Insert" href="#nlm42230-3" class="nlmlinkfalse">Patient Package Insert</a></li><li><a title="Highlights" href="#nlmhighlights" class="nlmlinktrue">Highlights</a></li><li><a title="Full Table of Contents" href="javascript:nlmftoc('nlmftoc');" class="nlmlinktrue">Full Table of Contents</a></li><li><a href="#" class="nlmlinkfalse">Medication Guide</a></li></ul></div></fieldset></div><div class="spl">	<a name="druglabelcontent"></a><div id="nlmhighlightsmarker"><div class="Highlights" id="Highlights"><table border="0" style="table-layout:fixed" width="100%" cellpadding="5" cellspacing="5"><tr><td valign="top" align="left" width="50%"><div><a name="nlmhighlights"><h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1></a><div class="HighlightsDisclaimer">These highlights do not include all the information needed to use <br>PLAVIX safely and effectively. See full prescribing information for <br>PLAVIX. <br>&nbsp; <br>PLAVIX (clopidogrel bisulfate) tablets <br>Initial U.S. Approval: 1997</div><div class="Warning"><div><h1 class="Warning">WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS</h1><h1 class="Warning"> See full prescribing information for complete boxed warning. </h1><ul><li><span class="Bold">Effectiveness of Plavix depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. (<a href="#i4i_section_id_dc403c5d-11a6-40bb-8ef4-45d1152da657">5.1</a>) </span></li><li><span class="Bold">Poor metabolizers treated with Plavix at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function. (<a href="#i4i_section_id_8d9d2893-f62c-49bc-b79e-6eec96754a4c">12.5</a>)</span></li><li><span class="Bold">Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. (<a href="#i4i_section_id_8d9d2893-f62c-49bc-b79e-6eec96754a4c">12.5</a>)</span></li><li><span class="Bold">Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. (<a href="#i4i_section_id_4b3b68b5-2ed5-4399-b3a0-d7a59427953a">2.3</a>, <a href="#i4i_section_id_dc403c5d-11a6-40bb-8ef4-45d1152da657">5.1</a>)</span></li></ul></div></div><div class="HighlightSection"><h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1><div><a name="id_d4770831-ae22-424d-b990-1959d77d7466"></a><table><col align="left" width="50%"><col align="left" width="50%"><tbody class="Headless"><tr class="First Toprule"><td align="left" valign="top">Boxed Warning</td><td align="left" valign="top">03/2010</td></tr><tr><td align="left" valign="top">Dosage and Administration (<a href="#i4i_section_id_4b3b68b5-2ed5-4399-b3a0-d7a59427953a">2.3</a>)</td><td align="left" valign="top">03/2010</td></tr><tr class="Botrule Last"><td align="left" valign="top">Warnings and Precautions (<a href="#i4i_section_id_dc403c5d-11a6-40bb-8ef4-45d1152da657">5.1</a>, <a href="#i4i_section_id_6a1aa4ec-a276-4f8b-a14c-d534a171a924">5.2</a>, <a href="#i4i_section_id_07069411-7f0d-4ea5-b37d-960f59f9e3bb">5.3</a>)</td><td align="left" valign="top">03/2010</td></tr></tbody></table></div></div><div></div><div class="HighlightSection"><h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1><div><p class="Highlights">Plavix is a P2Y<span class="Sub">12</span> platelet inhibitor indicated for: </p><ul><li>Acute coronary syndrome </li><li>Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. (<a href="#i4i_section_id_9ffd2431-216e-4bc6-b9c5-59f870d5001e">1.2</a>)</li></ul></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1><div><ul><li>Acute coronary syndrome (<a href="#i4i_section_id_9b570422-6d50-44af-8a02-b29f81ed718c">2.1</a>) </li><li>Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily (<a href="#i4i_section_id_1df46418-8cc3-4051-8cbf-54b2d120db41">2.2</a>)</li></ul></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1><div><p class="Highlights">Tablets: 75 mg, 300 mg (<a href="#i4i_dosage_form_strength_id_d5ccda12-ab5d-4fde-8780-e588448d12f6">3</a>) </p></div></div><div class="HighlightSection"><h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1><div><ul><li>Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage (<a href="#i4i_section_id_5e24c873-6a9f-4e25-82f4-2e2c070d0748">4.1</a>)</li><li>Hypersensitivity to clopidogrel or any component of the product (<a href="#i4i_section_id_9b2ad0f7-5541-468e-b178-037e1c1d99dc">4.2</a>)</li></ul></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1><div><ul><li>Reduced effectiveness in impaired CYP2C19 function: Avoid concomitant use with drugs that inhibit CYP2C19 (e.g., omeprazole). (<a href="#i4i_section_id_dc403c5d-11a6-40bb-8ef4-45d1152da657">5.1</a>)</li><li>Bleeding: Plavix increases risk of bleeding. Discontinue 5 days prior to elective surgery. (<a href="#i4i_section_id_6a1aa4ec-a276-4f8b-a14c-d534a171a924">5.2</a>)</li><li>Discontinuation of Plavix: Premature discontinuation increases risk of cardiovascular events. (<a href="#i4i_section_id_07069411-7f0d-4ea5-b37d-960f59f9e3bb">5.3</a>)</li><li>Recent transient ischemic attack or stroke: Combination use of Plavix and aspirin in these patients was not shown to be more effective than Plavix alone, but was shown to increase major bleeding. (<a href="#i4i_section_id_763dc195-352c-455d-88c5-976dc6bc77af">5.4</a>)</li><li>Thrombotic thrombocytopenic purpura (TTP): TTP has been reported with Plavix, including fatal cases. (<a href="#i4i_section_id_6a1a118e-f986-48f9-ac54-3278fa458315">5.5</a>)</li></ul></div><div></div><div></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1><div><p class="Highlights">Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction. (<a href="#i4i_section_id_b0f9463b-170c-46d1-8aca-7e115d88e288">6.1</a>) </p><br><p class="Highlights"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1><div><ul><li>CYP2C19 inhibitors (e.g., omeprazole): Avoid concomitant use. (<a href="#i4i_section_id_e5f0b0bc-34a0-4ecb-b925-368d85c21415">7.1</a>)</li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs): Combination use increases risk of gastrointestinal bleeding. (<a href="#i4i_section_id_c46957ce-bde8-447a-ab6c-34dac4194255">7.2</a>)</li><li>Warfarin: Combination use increases risk of bleeding. (<a href="#i4i_section_id_32ba52ca-4d47-4d01-91bf-4bb94d46fbcb">7.3</a>)</li></ul></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1><div><p class="Highlights">Nursing mothers: Discontinue drug or nursing, taking into consideration importance of drug to mother. (<a href="#i4i_nursing_mothers_id_c72563db-f5bf-4771-a6dd-69beefd48849">8.3</a>)  </p></div><div></div><div></div><div></div><div></div><div></div></div><div></div><div></div><div><div></div><div></div><div></div><div></div></div><div><div></div></div><div><div><div></div><div></div><div></div></div><div><div></div></div><div></div></div><div><div></div></div><div><div></div><div></div><div></div><div></div><div></div></div><div></div><div></div><p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p><p class="HighlightsRevision">Revised: 12/2010</p></div></td></tr></table></div></div><div id="nlmftoc"><span id="backtodmsections"><a title=" Back to Highlights and Tabs " href="javascript:nlmftoc('backtodmsections');">Back to Highlights and Tabs</a></span><div class="Index" id="Index"><table style="table-layout:fixed" width="100%" cellpadding="5" cellspacing="5"><tr><td valign="top" align="left" width="50%"><div><h1 class="Colspan"><a style="text-decoration:none;" name="dmsections">FULL PRESCRIBING INFORMATION: CONTENTS</a><a name="footnote-reference-content" href="#footnote-content">*</a></h1><h1><a href="#section-1" class="toc">WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS</a></h1><h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1><h2><a href="#section-1.1" class="toc">1.1 Acute Coronary Syndrome (ACS)</a></h2><h2><a href="#section-1.2" class="toc">1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease</a></h2><h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1><h2><a href="#section-2.1" class="toc">2.1 Acute Coronary Syndrome</a></h2><h2><a href="#section-2.2" class="toc">2.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease</a></h2><h2><a href="#section-2.3" class="toc">2.3 CYP2C19 Poor Metabolizers</a></h2><h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1><h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1><h2><a href="#section-4.1" class="toc">4.1 Active Bleeding</a></h2><h2><a href="#section-4.2" class="toc">4.2 Hypersensitivity </a></h2><h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1><h2><a href="#section-5.1" class="toc">5.1 Diminished Antiplatelet Activity Due to Impaired CYP2C19 Function</a></h2><h2><a href="#section-5.2" class="toc">5.2 General Risk of Bleeding</a></h2><h2><a href="#section-5.3" class="toc">5.3 Discontinuation of Plavix</a></h2><h2><a href="#section-5.4" class="toc">5.4 Patients with Recent Transient Ischemic Attack (TIA) or Stroke</a></h2><h2><a href="#section-5.5" class="toc">5.5 Thrombotic Thrombocytopenic Purpura (TTP)</a></h2><h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1><h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2><h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2><h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1><h2><a href="#section-7.1" class="toc">7.1 CYP2C19 Inhibitors</a></h2><h2><a href="#section-7.2" class="toc">7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</a></h2><h2><a href="#section-7.3" class="toc">7.3 Warfarin (CYP2C9 Substrates) </a></h2><h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1><h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2><h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2><h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2><h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2><h2><a href="#section-8.5" class="toc">8.6 Renal Impairment</a></h2><h2><a href="#section-8.6" class="toc">8.7 Hepatic Impairment</a></h2><h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1><h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1><h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1><h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2><h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2><h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2><h2><a href="#section-11.4" class="toc">12.5 Pharmacogenomics</a></h2><h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1><h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2><h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1><h2><a href="#section-13.1" class="toc">14.1 Acute Coronary Syndrome </a></h2><h2><a href="#section-13.2" class="toc">14.2 Recent Myocardial Infarction, Recent Stroke, or Established Peripheral Arterial Disease</a></h2><h2><a href="#section-13.3" class="toc">14.3 Lack of Established Benefit of Plavix plus Aspirin in Patients with Multiple Risk Factors or Established Vascular Disease</a></h2><h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1><h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1><h2><a href="#section-15.1" class="toc">17.1 Benefits and Risks</a></h2><h2><a href="#section-15.2" class="toc">17.2 Bleeding</a></h2><h2><a href="#section-15.3" class="toc">17.3 Other Signs and Symptoms Requiring Medical Attention</a></h2><h2><a href="#section-15.4" class="toc">17.4 Invasive Procedures</a></h2><h2><a href="#section-15.5" class="toc">17.5 Concomitant Medications</a></h2><dl class="Footnote"><dt><a name="footnote-content" href="#footnote-reference-content">*</a></dt><dd>Sections or subsections omitted from the full prescribing information are not listed.</dd></dl></div></td></tr></table></div></div><div class="Contents"><h1>FULL PRESCRIBING INFORMATION</h1><div class="Section" data-sectionCode="48780-1"><a name="section-1"></a><p></p></div><a name="nlm34066-1"></a><div class="Warning"><a name="id_c9c1ed04-52d4-4e6f-a05c-88e086263e5b"></a><a name="section-1"></a><p></p><h1><a></a>WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS</h1><p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="Bold">The effectiveness of Plavix is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 <span class="Italics">[see <a href="#i4i_section_id_dc403c5d-11a6-40bb-8ef4-45d1152da657">Warnings and Precautions (5.1)</a>]</span>. Plavix at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers. Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with Plavix at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy <span class="Italics">[see <a href="#i4i_section_id_8d9d2893-f62c-49bc-b79e-6eec96754a4c">Clinical Pharmacology (12.5)</a>]</span>. Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers <span class="Italics">[see <a href="#i4i_section_id_4b3b68b5-2ed5-4399-b3a0-d7a59427953a">Dosage and Administration (2.3)</a>]</span>.</span></span></p></div><div class="Section" data-sectionCode="34067-9"><a name="i4i_indications_id_b7e539c6-c4f4-40bc-acdf-a7e2b5838b1c"></a><a name="section-1"></a><p></p><h1><a name="nlm34067-9"></a>1 INDICATIONS AND USAGE</h1><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_81495674-f753-4926-a24b-1a0e1a551ee6"></a><a name="section-1.1"></a><p></p><h2><a name="nlm42229-5"></a>1.1 Acute Coronary Syndrome (ACS)</h2><ul><li>For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.</li><li>For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary percutaneous coronary intervention is unknown.</li></ul><p class="First">The optimal duration of Plavix therapy in ACS is unknown. </p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_9ffd2431-216e-4bc6-b9c5-59f870d5001e"></a><a name="section-1.2"></a><p></p><h2><a name="nlm42229-5"></a>1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease</h2><p class="First">For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.</p></div></div><div class="Section" data-sectionCode="34068-7"><a name="i4i_dosage_admin_id_9601fc25-e7dd-44d2-9c87-ce75182dd037"></a><a name="section-2"></a><p></p><h1><a name="nlm34068-7"></a>2 DOSAGE AND ADMINISTRATION</h1><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_9b570422-6d50-44af-8a02-b29f81ed718c"></a><a name="section-2.1"></a><p></p><h2><a name="nlm42229-5"></a>2.1 Acute Coronary Syndrome</h2><p class="First">Plavix can be administered with or without food <span class="Italics">[see <a href="#i4i_pharmacokinetics_id_55403278-c3bc-414b-b8b7-6dc3ad8e525e">Clinical Pharmacology (12.3)</a>]</span></p><ul><li>For patients with non-ST-elevation ACS (UA/NSTEMI), initiate Plavix with a single 300 mg oral loading dose and then continue at 75 mg once daily. Initiate aspirin (75&ndash;325 mg once daily) and continue in combination with Plavix <span class="Italics">[see <a href="#i4i_section_id_91a6cb1c-175d-49dd-b4a6-297ce3b606aa">Clinical Studies (14.1)</a>]</span>.</li><li>For patients with STEMI, the recommended dose of Plavix is 75 mg once daily orally, administered in combination with aspirin (75&ndash;325 mg once daily), with or without thrombolytics. Plavix may be initiated with or without a loading dose <span class="Italics">[see <a href="#i4i_section_id_91a6cb1c-175d-49dd-b4a6-297ce3b606aa">Clinical Studies (14.1)</a>]</span>.</li></ul></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_1df46418-8cc3-4051-8cbf-54b2d120db41"></a><a name="section-2.2"></a><p></p><h2><a name="nlm42229-5"></a>2.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease</h2><p class="First">The recommended daily dose of Plavix is 75 mg once daily orally, with or without food <span class="Italics">[see<a href="#i4i_pharmacokinetics_id_55403278-c3bc-414b-b8b7-6dc3ad8e525e"> Clinical Pharmacology (12.3)</a>]</span>.</p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_4b3b68b5-2ed5-4399-b3a0-d7a59427953a"></a><a name="section-2.3"></a><p></p><h2><a name="nlm42229-5"></a>2.3 CYP2C19 Poor Metabolizers</h2><p class="First" style="border-left:1px solid;"><span class="XmChange">CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen (600 mg loading dose followed by 150 mg once daily) in poor metabolizers increases antiplatelet response <span class="Italics">[see <a href="#i4i_section_id_8d9d2893-f62c-49bc-b79e-6eec96754a4c">Clinical Pharmacology (12.5)</a>]</span>, an appropriate dose regimen for this patient population has not been established in clinical outcome trials.</span></p></div></div><div class="Section" data-sectionCode="43678-2"><a name="i4i_dosage_form_strength_id_d5ccda12-ab5d-4fde-8780-e588448d12f6"></a><a name="section-3"></a><p></p><h1><a name="nlm43678-2"></a>3 DOSAGE FORMS AND STRENGTHS</h1><ul><li>75 mg tablets: Pink, round, biconvex, film-coated tablets debossed with "75" on one side and "1171" on the other </li><li>300 mg tablets: Pink, oblong, film-coated tablets debossed with "300" on one side and "1332" on the other</li></ul></div><div class="Section" data-sectionCode="34070-3"><a name="i4i_contraindications_id_9a727688-d2d7-4d22-a010-806cc75f014a"></a><a name="section-4"></a><p></p><h1><a name="nlm34070-3"></a>4 CONTRAINDICATIONS</h1><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_5e24c873-6a9f-4e25-82f4-2e2c070d0748"></a><a name="section-4.1"></a><p></p><h2><a name="nlm42229-5"></a>4.1 Active Bleeding</h2><p class="First">Plavix is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage.</p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_9b2ad0f7-5541-468e-b178-037e1c1d99dc"></a><a name="section-4.2"></a><p></p><h2><a name="nlm42229-5"></a>4.2 Hypersensitivity </h2><p class="First">Plavix is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any component of the product <span class="Italics">[see <a href="#i4i_section_id_2be570b3-11a6-4cf0-b482-0da111d06545">Adverse Reactions (6.2)</a>]</span>.</p></div></div><div class="Section" data-sectionCode="43685-7"><a name="i4i_warnings_precautions_id_7dd52f6d-724d-40f4-ba91-92c80743b456"></a><a name="section-5"></a><p></p><h1><a name="nlm43685-7"></a>5 WARNINGS AND PRECAUTIONS</h1><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_dc403c5d-11a6-40bb-8ef4-45d1152da657"></a><a name="section-5.1"></a><p></p><h2><a name="nlm42229-5"></a>5.1 Diminished Antiplatelet Activity Due to Impaired CYP2C19 Function</h2><p class="First" style="border-left:1px solid;"><span class="XmChange">Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 <span class="Italics">[see Boxed Warning]</span> and by concomitant medications that interfere with CYP2C19. Avoid concomitant use of Plavix and drugs that inhibit CYP2C19 activity. Co-administration of Plavix with omeprazole, a proton pump inhibitor that is an inhibitor of CYP2C19, reduces the pharmacological activity of Plavix if given concomitantly or if given 12 hours apart <span class="Italics">[see <a href="#i4i_section_id_e5f0b0bc-34a0-4ecb-b925-368d85c21415">Drug Interactions (7.1)</a>]</span>.</span></p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_6a1aa4ec-a276-4f8b-a14c-d534a171a924"></a><a name="section-5.2"></a><p></p><h2><a name="nlm42229-5"></a>5.2 General Risk of Bleeding</h2><p class="First" style="border-left:1px solid;"><span class="XmChange">Thienopyridines, including Plavix, increase the risk of bleeding. If a patient is to undergo surgery and an antiplatelet effect is not desired, discontinue Plavix 5 days prior to surgery. In patients who stopped therapy more than five days prior to CABG the rates of major bleeding were similar (event rate 4.4% Plavix + aspirin; 5.3% placebo + aspirin). In patients who remained on therapy within five days of CABG, the major bleeding rate was 9.6% for Plavix + aspirin, and 6.3% for placebo + aspirin.</span></p><p style="border-left:1px solid;"><span class="XmChange">Thienopyridines inhibit platelet aggregation for the lifetime of the platelet (7&ndash;10 days), so withholding a dose will not be useful in managing a bleeding event or the risk of bleeding associated with an invasive procedure. Because the half-life of clopidogrel's active metabolite is short, it may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective.</span></p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_07069411-7f0d-4ea5-b37d-960f59f9e3bb"></a><a name="section-5.3"></a><p></p><h2><a name="nlm42229-5"></a>5.3 Discontinuation of Plavix</h2><p class="First" style="border-left:1px solid;"><span class="XmChange">Avoid lapses in therapy, and if Plavix must be temporarily discontinued, restart as soon as possible. Premature discontinuation of Plavix may increase the risk of cardiovascular events.</span></p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_763dc195-352c-455d-88c5-976dc6bc77af"></a><a name="section-5.4"></a><p></p><h2><a name="nlm42229-5"></a>5.4 Patients with Recent Transient Ischemic Attack (TIA) or Stroke</h2><p class="First">In patients with recent TIA or stroke who are at high risk for recurrent ischemic events, the combination of aspirin and Plavix has not been shown to be more effective than Plavix alone, but the combination has been shown to increase major bleeding.</p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_6a1a118e-f986-48f9-ac54-3278fa458315"></a><a name="section-5.5"></a><p></p><h2><a name="nlm42229-5"></a>5.5 Thrombotic Thrombocytopenic Purpura (TTP)</h2><p class="First">TTP, sometimes fatal, has been reported following use of Plavix, sometimes after a short exposure (&lt;2 weeks). TTP is a serious condition that requires urgent treatment including plasmapheresis (plasma exchange). It is characterized by thrombocytopenia, microangiopathic hemolytic anemia (schistocytes [fragmented RBCs] seen on peripheral smear), neurological findings, renal dysfunction, and fever <span class="Italics">[see <a href="#i4i_section_id_2be570b3-11a6-4cf0-b482-0da111d06545">Adverse Reactions (6.2)</a>]</span>.</p></div></div><div class="Section" data-sectionCode="34084-4"><a name="i4i_adverse_effects_id_60b648c5-125a-4c9b-b6e3-fa0efe480939"></a><a name="section-6"></a><p></p><h1><a name="nlm34084-4"></a>6 ADVERSE REACTIONS</h1><p class="First">The following serious adverse reactions are discussed below and elsewhere in the labeling:</p><ul><li>Bleeding <span class="Italics">[see <a href="#i4i_section_id_6a1aa4ec-a276-4f8b-a14c-d534a171a924">Warnings and Precautions (5.2)</a>]</span></li><li>Thrombotic thrombocytopenic purpura <span class="Italics">[see <a href="#i4i_section_id_6a1a118e-f986-48f9-ac54-3278fa458315">Warnings and Precautions (5.5)</a>]</span></li></ul><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_b0f9463b-170c-46d1-8aca-7e115d88e288"></a><a name="section-6.1"></a><p></p><h2><a name="nlm42229-5"></a>6.1 Clinical Studies Experience</h2><p class="First">Because clinical trials are conducted under widely varying conditions and durations of follow up, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p>Plavix has been evaluated for safety in more than 54,000 patients, including over 21,000 patients treated for 1 year or more. The clinically important adverse reactions observed in trials comparing Plavix plus aspirin to placebo plus aspirin and trials comparing Plavix alone to aspirin alone are discussed below. </p><p><span class="Underline"><span class="Italics">Bleeding</span></span></p><p><span class="Italics">CURE</span></p><p>In CURE, Plavix use with aspirin was associated with an increase in major bleeding (primarily gastrointestinal and at puncture sites) compared to placebo with aspirin (see Table 1). The incidence of intracranial hemorrhage (0.1%) and fatal bleeding (0.2%) were the same in both groups. Other bleeding events that were reported more frequently in the clopidogrel group were epistaxis, hematuria, and bruise.</p><p>The overall incidence of bleeding is described in Table 1. </p><a name="id_bbcd8197-1404-4fd2-a23a-4f5e376d84ee"></a><table><caption><span>Table 1: CURE Incidence of Bleeding Complications (% patients)</span></caption><col align="left" width="40%"><col align="center" width="20%"><col align="center" width="20%"><col align="center" width="20%"><thead><tr class="First Toprule"><td class="Botrule Rrule" align="left" valign="top">Event</td><td class="Botrule Rrule" align="left" valign="top">Plavix<br> (+ aspirin)<a class="Sup" href="#footnote-1" name="footnote-reference-1">*</a></td><td class="Botrule Rrule" align="left" valign="top">Placebo<br> (+ aspirin)<a class="Sup" href="#footnote-1">*</a></td><td class="Botrule Lrule" align="left" valign="top">p-value</td></tr><tr class="Botrule Last"><td class="Rrule" align="left" valign="top"></td><td class="Rrule" align="left" valign="top">(n=6259)</td><td class="Rrule" align="left" valign="top">(n=6303)</td><td align="left" valign="top"></td></tr></thead><tfoot><tr><td align="left" colspan="4"><dl class="Footnote"><dt><a href="#footnote-reference-1" name="footnote-1">*</a></dt><dd>Other standard therapies were used as appropriate.</dd><dt><a href="#footnote-reference-2" name="footnote-2">&dagger;</a></dt><dd>Life-threatening and other major bleeding.</dd><dt><a href="#footnote-reference-3" name="footnote-3">&Dagger;</a></dt><dd>Major bleeding event rate for Plavix + aspirin was dose-dependent on aspirin: &lt;100 mg = 2.6%; 100&ndash;200 mg = 3.5%; &gt;200 mg = 4.9%<br>Major bleeding event rates for Plavix + aspirin by age were: &lt;65 years = 2.5%, &ge;65 to &lt;75 years = 4.1%, &ge;75 years = 5.9%</dd><dt><a href="#footnote-reference-4" name="footnote-4">&sect;</a></dt><dd>Major bleeding event rate for placebo + aspirin was dose-dependent on aspirin: &lt;100 mg = 2.0%; 100&ndash;200 mg = 2.3%; &gt;200 mg = 4.0%<br>Major bleeding event rates for placebo + aspirin by age were: &lt;65 years = 2.1%, &ge;65 to &lt;75 years = 3.1%, &ge;75 years = 3.6%</dd><dt><a href="#footnote-reference-5" name="footnote-5">&para;</a></dt><dd>Led to interruption of study medication.</dd></dl></td></tr></tfoot><tbody><tr class="First Toprule"><td align="left" valign="top">Major bleeding <a class="Sup" href="#footnote-2" name="footnote-reference-2">&dagger;</a></td><td class="Toprule" align="left" valign="top">3.7 <a class="Sup" href="#footnote-3" name="footnote-reference-3">&Dagger;</a></td><td class="Toprule" align="left" valign="top">2.7 <a class="Sup" href="#footnote-4" name="footnote-reference-4">&sect;</a></td><td align="left" valign="top">0.001</td></tr><tr><td align="left" valign="top">&nbsp;&nbsp;Life-threatening bleeding</td><td align="left" valign="top">2.2</td><td align="left" valign="top">1.8</td><td align="left" valign="top">0.13</td></tr><tr><td align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Fatal</td><td align="left" valign="top">0.2</td><td align="left" valign="top">0.2</td><td align="left" valign="top"></td></tr><tr><td align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;5 g/dL hemoglobin drop</td><td align="left" valign="top">0.9</td><td align="left" valign="top">0.9</td><td align="left" valign="top"></td></tr><tr><td align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Requiring surgical intervention</td><td align="left" valign="top">0.7</td><td align="left" valign="top">0.7</td><td align="left" valign="top"></td></tr><tr><td align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Hemorrhagic strokes</td><td align="left" valign="top">0.1</td><td align="left" valign="top">0.1</td><td align="left" valign="top"></td></tr><tr><td align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Requiring inotropes</td><td align="left" valign="top">0.5</td><td align="left" valign="top">0.5</td><td align="left" valign="top"></td></tr><tr><td align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Requiring transfusion (&ge;4 units)</td><td align="left" valign="top">1.2</td><td align="left" valign="top">1.0</td><td align="left" valign="top"></td></tr><tr><td align="left" valign="top">Other major bleeding</td><td align="left" valign="top">1.6</td><td align="left" valign="top">1.0</td><td align="left" valign="top">0.005</td></tr><tr><td align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Significantly disabling</td><td align="left" valign="top">0.4</td><td align="left" valign="top">0.3</td><td align="left" valign="top"></td></tr><tr><td align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Intraocular bleeding with significant loss of vision</td><td align="left" valign="top">0.05</td><td align="left" valign="top">0.03</td><td align="left" valign="top"></td></tr><tr><td align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Requiring 2&ndash;3 units of blood</td><td align="left" valign="top">1.3</td><td align="left" valign="top">0.9</td><td align="left" valign="top"></td></tr><tr class="Botrule Last"><td align="left" valign="top">Minor bleeding <a class="Sup" href="#footnote-5" name="footnote-reference-5">&para;</a></td><td align="left" valign="top">5.1</td><td align="left" valign="top">2.4</td><td align="left" valign="top">&lt; 0.001</td></tr></tbody></table><p>Ninety-two percent (92%) of the patients in the CURE study received heparin or low molecular weight heparin (LMWH), and the rate of bleeding in these patients was similar to the overall results.</p><p><span class="Italics">COMMIT</span></p><p>In COMMIT, similar rates of major bleeding were observed in the Plavix and placebo groups, both of which also received aspirin (see Table 2). </p><a name="id_83ab4265-d38e-4c53-b584-5a411dbe11c3"></a><table><caption><span>Table 2: Incidence of Bleeding Events in COMMIT (% patients)</span></caption><col align="left" width="40%"><col align="center" width="20%"><col align="center" width="20%"><col align="center" width="20%"><thead><tr class="Botrule First Last"><td class="Lrule Rrule" align="left" valign="top">Type of bleeding</td><td class="Rrule" align="left" valign="top">Plavix<br>(+ aspirin)<br>(n=22961)</td><td class="Rrule" align="left" valign="top">Placebo<br>(+ aspirin)<br>(n=22891)</td><td class="Rrule" align="left" valign="top">p-value</td></tr></thead><tfoot><tr><td align="left" colspan="4"><dl class="Footnote"><dt><a href="#footnote-reference-6" name="footnote-6">*</a></dt><dd>Major bleeds were cerebral bleeds or non-cerebral bleeds thought to have caused death or that required transfusion.</dd><dt><a href="#footnote-reference-7" name="footnote-7">&dagger;</a></dt><dd>The relative rate of major noncerebral or cerebral bleeding was independent of age. Event rates for Plavix + aspirin by age were: &lt;60 years = 0.3%, &ge;60 to &lt;70 years = 0.7%, &ge;70 years = 0.8%. Event rates for placebo + aspirin by age were: &lt;60 years = 0.4%, &ge;60 to &lt;70 years = 0.6%, &ge;70 years = 0.7%.</dd></dl></td></tr></tfoot><tbody><tr class="First Toprule"><td class="Lrule Rrule" align="left" valign="top">Major<a class="Sup" href="#footnote-6" name="footnote-reference-6">*</a> noncerebral or cerebral bleeding<a class="Sup" href="#footnote-7" name="footnote-reference-7">&dagger;</a></td><td class="Rrule" align="left" valign="top">0.6</td><td class="Rrule" align="left" valign="top">0.5</td><td class="Rrule" align="left" valign="top">0.59</td></tr><tr><td class="Lrule Rrule" align="left" valign="top">&nbsp;&nbsp;Major noncerebral</td><td class="Rrule" align="left" valign="top">0.4</td><td class="Rrule" align="left" valign="top">0.3</td><td class="Rrule" align="left" valign="top">0.48</td></tr><tr><td class="Lrule Rrule" align="left" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;Fatal</td><td class="Rrule" align="left" valign="top">0.2</td><td class="Rrule" align="left" valign="top">0.2</td><td class="Rrule" align="left" valign="top">0.90</td></tr><tr><td class="Lrule Rrule" align="left" valign="top">Hemorrhagic stroke </td><td class="Rrule" align="left" valign="top">0.2</td><td class="Rrule" align="left" valign="top">0.2</td><td class="Rrule" align="left" valign="top">0.91</td></tr><tr><td class="Lrule Rrule" align="left" valign="top">&nbsp;&nbsp;Fatal</td><td class="Rrule" align="left" valign="top">0.2</td><td class="Rrule" align="left" valign="top">0.2</td><td class="Rrule" align="left" valign="top">0.81</td></tr><tr><td class="Lrule Rrule" align="left" valign="top">Other noncerebral bleeding (non-major)</td><td class="Rrule" align="left" valign="top">3.6</td><td class="Rrule" align="left" valign="top">3.1</td><td class="Rrule" align="left" valign="top">0.005</td></tr><tr class="Botrule Last"><td class="Lrule Rrule" align="left" valign="top">Any noncerebral bleeding</td><td class="Rrule" align="left" valign="top">3.9</td><td class="Rrule" align="left" valign="top">3.4</td><td class="Rrule" align="left" valign="top">0.004</td></tr></tbody></table><p><span class="Italics">CAPRIE (Plavix vs. Aspirin)</span></p><p>In CAPRIE, gastrointestinal hemorrhage occurred at a rate of 2.0% in those taking Plavix vs. 2.7% in those taking aspirin; bleeding requiring hospitalization occurred in 0.7% and 1.1%, respectively. The incidence of intracranial hemorrhage was 0.4% for Plavix compared to 0.5% for aspirin.</p><p>Other bleeding events that were reported more frequently in the Plavix group were epistaxis and hematoma.</p><p> Other Adverse Events </p><p>In CURE and CHARISMA, which compared Plavix plus aspirin to aspirin alone, there was no difference in the rate of adverse events (other than bleeding) between Plavix and placebo.</p><p>In CAPRIE, which compared Plavix to aspirin, pruritus was more frequently reported in those taking Plavix. No other difference in the rate of adverse events (other than bleeding) was reported.</p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_2be570b3-11a6-4cf0-b482-0da111d06545"></a><a name="section-6.2"></a><p></p><h2><a name="nlm42229-5"></a>6.2 Postmarketing Experience</h2><p class="First">The following adverse reactions have been identified during post-approval use of Plavix. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p><ul><li><span class="Italics">Blood and lymphatic system disorders</span>: Agranulocytosis, aplastic anemia/pancytopenia, thrombotic thrombocytopenic purpura (TTP)</li><li><span class="Italics">Gastrointestinal disorders:</span> Gastrointestinal and retroperitoneal hemorrhage with fatal outcome, colitis (including ulcerative or lymphocytic colitis), pancreatitis, stomatitis</li><li><span class="Italics">General disorders and administration site condition</span>: Fever, hemorrhage of operative wound</li><li><span class="Italics">Hepato-biliary disorders:</span> Acute liver failure, hepatitis (non-infectious), abnormal liver function test</li><li><span class="Italics">Immune system disorders:</span> Hypersensitivity reactions, anaphylactoid reactions, serum sickness</li><li><span class="Italics">Musculoskeletal, connective tissue and bone disorders:</span> Musculoskeletal bleeding, myalgia, arthralgia, arthritis</li><li><span class="Italics">Nervous system disorders</span>: Taste disorders, fatal intracranial bleeding</li><li><span class="Italics">Eye disorders</span>: Eye (conjunctival, ocular, retinal) bleeding</li><li><span class="Italics">Psychiatric disorders:</span> Confusion, hallucinations </li><li><span class="Italics">Respiratory, thoracic and mediastinal disorders:</span> Bronchospasm, interstitial pneumonitis, respiratory tract bleeding</li><li><span class="Italics">Renal and urinary disorders:</span> Glomerulopathy, increased creatinine levels</li><li><span class="Italics">Skin and subcutaneous tissue disorders:</span> Maculopapular or erythematous rash, urticaria, bullous dermatitis, eczema, toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema, erythema multiforme, skin bleeding, lichen planus</li><li><span class="Italics">Vascular disorders:</span> Vasculitis, hypotension</li></ul></div></div><div class="Section" data-sectionCode="34073-7"><a name="i4i_interactions_id_95497093-6d97-4cfb-9459-33be6e1f979b"></a><a name="section-7"></a><p></p><h1><a name="nlm34073-7"></a>7 DRUG INTERACTIONS</h1><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_e5f0b0bc-34a0-4ecb-b925-368d85c21415"></a><a name="section-7.1"></a><p></p><h2><a name="nlm42229-5"></a>7.1 CYP2C19 Inhibitors</h2><p class="First">Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of drugs that inhibit the activity of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition. Avoid concomitant use of drugs that inhibit CYP2C19, e.g., omeprazole <span class="Italics">[see <a href="#i4i_section_id_dc403c5d-11a6-40bb-8ef4-45d1152da657">Warnings and Precautions (5.1) </a>and <a href="#i4i_section_id_8d9d2893-f62c-49bc-b79e-6eec96754a4c">Clinical Pharmacology (12.5)</a>]</span>.</p><p><span class="Underline"><span class="Italics">Omeprazole</span></span></p><p>In a crossover clinical study, 72 healthy subjects were administered Plavix (300 mg loading dose followed by 75 mg per day) alone and with omeprazole (80 mg at the same time as Plavix) for 5 days. The exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5) when Plavix and omeprazole were administered together. Mean inhibition of platelet aggregation was diminished by 47% (24 hours) and 30% (Day 5) when Plavix and omeprazole were administered together. </p><p>In another study, 72 healthy subjects were given the same doses of Plavix and omeprazole but the drugs were administered 12 hours apart; the results were similar, indicating that administering Plavix and omeprazole at different times does not prevent their interaction <span class="Italics">[see <a href="#i4i_section_id_dc403c5d-11a6-40bb-8ef4-45d1152da657">Warnings and Precautions (5.1)</a>]</span>.</p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_c46957ce-bde8-447a-ab6c-34dac4194255"></a><a name="section-7.2"></a><p></p><h2><a name="nlm42229-5"></a>7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</h2><p class="First">Coadministration of Plavix and NSAIDs increases the risk of gastrointestinal bleeding.</p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_32ba52ca-4d47-4d01-91bf-4bb94d46fbcb"></a><a name="section-7.3"></a><p></p><h2><a name="nlm42229-5"></a>7.3 Warfarin (CYP2C9 Substrates) </h2><p class="First">Although the administration of clopidogrel 75 mg per day did not modify the pharmacokinetics of S-warfarin (a CYP2C9 substrate) or INR in patients receiving long-term warfarin therapy, coadministration of Plavix with warfarin increases the risk of bleeding because of independent effects on hemostasis.</p><p>However, at high concentrations <span class="Italics">in vitro</span>, clopidogrel inhibits CYP2C9.</p></div></div><div class="Section" data-sectionCode="43684-0"><a name="i4i_specific_populations_id_eba25790-8ec0-4b55-b365-6ca09ea627d0"></a><a name="section-8"></a><p></p><h1><a name="nlm43684-0"></a>8 USE IN SPECIFIC POPULATIONS</h1><div class="Section" data-sectionCode="42228-7"><a name="i4i_pregnancy_id_3607dddb-02d0-4d40-afc7-2cf68f49d1c1"></a><a name="section-8.1"></a><p></p><h2><a name="nlm42228-7"></a>8.1 Pregnancy</h2><p class="First"> Pregnancy Category B </p><p>Reproduction studies performed in rats and rabbits at doses up to 500 and 300 mg/kg/day, respectively (65 and 78 times the recommended daily human dose, respectively, on a mg/m<span class="Sup">2</span> basis), revealed no evidence of impaired fertility or fetotoxicity due to clopidogrel. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of a human response, Plavix should be used during pregnancy only if clearly needed.</p></div><div class="Section" data-sectionCode="34080-2"><a name="i4i_nursing_mothers_id_c72563db-f5bf-4771-a6dd-69beefd48849"></a><a name="section-8.2"></a><p></p><h2><a name="nlm34080-2"></a>8.3 Nursing Mothers</h2><p class="First">Studies in rats have shown that clopidogrel and/or its metabolites are excreted in the milk. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from clopidogrel, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p></div><div class="Section" data-sectionCode="34081-0"><a name="i4i_pediatric_use_id_6b120c8d-e3b3-474b-bb61-90efeb4fe836"></a><a name="section-8.3"></a><p></p><h2><a name="nlm34081-0"></a>8.4 Pediatric Use</h2><p class="First">Safety and effectiveness in the pediatric population have not been established.</p></div><div class="Section" data-sectionCode="34082-8"><a name="i4i_geriatric_use_id_3936ece9-cf58-404a-8b80-c1327563fe53"></a><a name="section-8.4"></a><p></p><h2><a name="nlm34082-8"></a>8.5 Geriatric Use</h2><p class="First">Of the total number of subjects in the CAPRIE and CURE controlled clinical studies, approximately 50% of patients treated with Plavix were 65 years of age and older, and 15% were 75 years and older. In COMMIT, approximately 58% of the patients treated with Plavix were 60 years and older, 26% of whom were 70 years and older.</p><p>The observed risk of thrombotic events with clopidogrel plus aspirin versus placebo plus aspirin by age category is provided in Figures 2 and 5 for the CURE and COMMIT trials, respectively <span class="Italics">[see <a href="#i4i_section_id_91a6cb1c-175d-49dd-b4a6-297ce3b606aa">Clinical Studies (14.1)</a>]</span>. The observed risk of bleeding events with clopidogrel plus aspirin versus placebo plus aspirin by age category is provided in Tables 1 and 2 for the CURE and COMMIT trials, respectively <span class="Italics">[see <a href="#i4i_section_id_b0f9463b-170c-46d1-8aca-7e115d88e288">Adverse Reactions (6.1)</a>]</span>. No dosage adjustment is necessary in elderly patients.</p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_f08d9f56-375e-4525-b01f-92ae289c9326"></a><a name="section-8.5"></a><p></p><h2><a name="nlm42229-5"></a>8.6 Renal Impairment</h2><p class="First">Experience is limited in patients with severe and moderate renal impairment <span class="Italics">[see <a href="#i4i_pharmacodynamics_id_c25c19fe-6a35-482e-ab8e-511e14b07543">Clinical Pharmacology (12.2)</a>]</span>.</p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_a0564298-dec4-4cae-aa0b-fedfd8a7de23"></a><a name="section-8.6"></a><p></p><h2><a name="nlm42229-5"></a>8.7 Hepatic Impairment</h2><p class="First">No dosage adjustment is necessary in patients with hepatic impairment <span class="Italics">[see <a href="#i4i_pharmacodynamics_id_c25c19fe-6a35-482e-ab8e-511e14b07543">Clinical Pharmacology (12.2)</a>]</span>.</p></div></div><div class="Section" data-sectionCode="34088-5"><a name="i4i_overdosage_id_7fe4144f-7293-4209-82d0-0b854c53db31"></a><a name="section-9"></a><p></p><h1><a name="nlm34088-5"></a>10 OVERDOSAGE</h1><p class="First">Platelet inhibition by Plavix is irreversible and will last for the life of the platelet. Overdose following clopidogrel administration may result in bleeding complications. A single oral dose of clopidogrel at 1500 or 2000 mg/kg was lethal to mice and to rats and at 3000 mg/kg to baboons. Symptoms of acute toxicity were vomiting, prostration, difficult breathing, and gastrointestinal hemorrhage in animals.</p><p>Based on biological plausibility, platelet transfusion may restore clotting ability.</p></div><div class="Section" data-sectionCode="34089-3"><a name="i4i_description_id_e0770946-34fe-4a85-beb7-817474e790d7"></a><a name="section-10"></a><p></p><h1><a name="nlm34089-3"></a>11 DESCRIPTION</h1><p class="First">Plavix (clopidogrel bisulfate) is a thienopyridine class inhibitor of P2Y<span class="Sub">12</span> ADP platelet receptors. Chemically it is methyl (+)-(<span class="Italics">S</span>)-?-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4<span class="Italics">H</span>)-acetate sulfate (1:1). The empirical formula of clopidogrel bisulfate is C<span class="Sub">16</span>H<span class="Sub">16</span>ClNO<span class="Sub">2</span>S&bull;H<span class="Sub">2</span>SO<span class="Sub">4</span> and its molecular weight is 419.9.</p><p>The structural formula is as follows:</p><div class="Figure"><img src="image.cfm?id=34869&type=img&name=1086a7b4%2Db89b%2D4bee%2D8120%2D5f752626c046%2D01.jpg" alt="Chemical Structure"></div><p>Clopidogrel bisulfate is a white to off-white powder. It is practically insoluble in water at neutral pH but freely soluble at pH 1. It also dissolves freely in methanol, dissolves sparingly in methylene chloride, and is practically insoluble in ethyl ether. It has a specific optical rotation of about +56&deg;.</p><p>Plavix for oral administration is provided as either pink, round, biconvex, debossed, film-coated tablets containing 97.875 mg of clopidogrel bisulfate which is the molar equivalent of 75 mg of clopidogrel base or pink, oblong, debossed film-coated tablets containing 391.5 mg of clopidogrel bisulfate which is the molar equivalent of 300 mg of clopidogrel base.</p><p>Each tablet contains hydrogenated castor oil, hydroxypropylcellulose, mannitol, microcrystalline cellulose and polyethylene glycol 6000 as inactive ingredients. The pink film coating contains ferric oxide, hypromellose 2910, lactose monohydrate, titanium dioxide and triacetin. The tablets are polished with Carnauba wax.</p></div><div class="Section" data-sectionCode="34090-1"><a name="i4i_clinical_pharmacology_id_c4e1adbf-9b1c-4548-9460-c97cb9f491f8"></a><a name="section-11"></a><p></p><h1><a name="nlm34090-1"></a>12 CLINICAL PHARMACOLOGY</h1><div class="Section" data-sectionCode="43679-0"><a name="i4i_mechanism_action_id_e8a2a537-c6cc-4189-ac50-2657dc09a6ec"></a><a name="section-11.1"></a><p></p><h2><a name="nlm43679-0"></a>12.1 Mechanism of Action</h2><p class="First">Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y<span class="Sub">12</span> class of ADP receptors on platelets.</p></div><div class="Section" data-sectionCode="43681-6"><a name="i4i_pharmacodynamics_id_c25c19fe-6a35-482e-ab8e-511e14b07543"></a><a name="section-11.2"></a><p></p><h2><a name="nlm43681-6"></a>12.2 Pharmacodynamics</h2><p class="First">Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y<span class="Sub">12</span> receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.</p><p>Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of Plavix. Repeated doses of 75 mg Plavix per day inhibit ADP-induced platelet aggregation on the first day, and inhibition reaches steady state between Day 3 and Day 7. At steady state, the average inhibition level observed with a dose of 75 mg Plavix per day was between 40% and 60%. Platelet aggregation and bleeding time gradually return to baseline values after treatment is discontinued, generally in about 5 days.</p><p><span class="Underline"><span class="Italics">Geriatric Patients</span></span></p><p>Elderly (&ge;75 years) and young healthy subjects had similar effects on platelet aggregation. </p><p><span class="Underline"><span class="Italics">Renally-Impaired Patients</span></span></p><p>After repeated doses of 75 mg Plavix per day, patients with severe renal impairment (creatinine clearance from 5 to 15 mL/min) and moderate renal impairment (creatinine clearance from 30 to 60 mL/min) showed low (25%) inhibition of ADP-induced platelet aggregation. </p><p><span class="Underline"><span class="Italics">Hepatically-Impaired Patients</span></span></p><p>After repeated doses of 75 mg Plavix per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects. </p><p><span class="Underline"><span class="Italics">Gender</span></span></p><p>In a small study comparing men and women, less inhibition of ADP-induced platelet aggregation was observed in women.</p></div><div class="Section" data-sectionCode="43682-4"><a name="i4i_pharmacokinetics_id_55403278-c3bc-414b-b8b7-6dc3ad8e525e"></a><a name="section-11.3"></a><p></p><h2><a name="nlm43682-4"></a>12.3 Pharmacokinetics</h2><p class="First">Clopidogrel is a prodrug and is metabolized to a pharmacologically active metabolite and inactive metabolites. </p><p><span class="Underline"><span class="Italics">Absorption</span></span></p><p>After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed. Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.</p><p><span class="Italics">Effect of Food</span></p><p>Plavix can be administered with or without food. In a study in healthy male subjects when Plavix 75 mg per day was given with a standard breakfast, mean inhibition of ADP-induced platelet aggregation was reduced by less than 9%. The active metabolite AUC<span class="Sub">0&ndash;24</span> was unchanged in the presence of food, while there was a 57% decrease in active metabolite Cmax. Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast. </p><p> Metabolism </p><p>Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes. Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite. Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel. This metabolic pathway is mediated by CYP2C19, CYP3A, CYP2B6 and CYP1A2. The active thiol metabolite binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation for the lifespan of the platelet.</p><p>The Cmax of the active metabolite is twice as high following a single 300 mg clopidogrel loading dose as it is after four days of 75 mg maintenance dose. Cmax occurs approximately 30 to 60 minutes after dosing. In the 75 to 300 mg dose range, the pharmacokinetics of the active metabolite deviates from dose proportionality: increasing the dose by a factor of four results in 2.0- and 2.7-fold increases in Cmax and AUC, respectively.</p><p> Elimination </p><p>Following an oral dose of <span class="Sup">14</span>C-labeled clopidogrel in humans, approximately 50% of total radioactivity was excreted in urine and approximately 46% in feces over the 5 days post-dosing. After a single, oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours. The half-life of the active metabolite is about 30 minutes. </p></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_8d9d2893-f62c-49bc-b79e-6eec96754a4c"></a><a name="section-11.4"></a><p></p><h2><a name="nlm42229-5"></a>12.5 Pharmacogenomics</h2><p class="First">CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by <span class="Italics">ex vivo</span> platelet aggregation assays, differ according to CYP2C19 genotype. Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel's active metabolite.</p><p>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to determine a patient's CYP2C19 genotype. </p><p>A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days. Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see <a href="#id_d6d7eefb-e17e-4785-aca7-764b5026e349">Table 3</a>). An appropriate dose regimen for this patient population has not been established in clinical outcome trials.</p><a name="id_d6d7eefb-e17e-4785-aca7-764b5026e349"></a><table><caption><span>Table 3: Active Metabolite Pharmacokinetics and Antiplatelet Responses by CYP2C19 Metabolizer Status</span></caption><col align="left" width="25%"><col align="left" width="15%"><col align="center" width="15%"><col align="center" width="15%"><col align="center" width="15%"><col align="center" width="15%"><thead><tr class="Botrule First Last"><td class="Lrule Rrule" align="left" valign="top"></td><td class="Rrule" align="left" valign="top">Dose</td><td class="Rrule" align="left" valign="top">Ultrarapid <br>(n=10)</td><td class="Rrule" align="left" valign="top">Extensive <br>(n=10)</td><td class="Rrule" align="left" valign="top">Intermediate <br>(n=10)</td><td class="Rrule" align="left" valign="top">Poor <br>(n=10)</td></tr></thead><tfoot><tr class="Last"><td class="Lrule Rrule" align="left" colspan="6" valign="top">Values are mean (SD)</td></tr><tr><td align="left" colspan="6"><dl class="Footnote"><dt><a href="#footnote-reference-8" name="footnote-8">*</a></dt><dd>Inhibition of platelet aggregation with 5&micro;M ADP; larger value indicates greater platelet inhibition</dd><dt><a href="#footnote-reference-9" name="footnote-9">&dagger;</a></dt><dd>Vasodilator-stimulated phosphoprotein &ndash; platelet reactivity index; smaller value indicates greater platelet inhibition</dd></dl></td></tr></tfoot><tbody><tr class="First Toprule"><td class="Lrule" align="left" valign="top">Cmax (ng/mL)</td><td class="Toprule" align="left" valign="top">300 mg (24 h)</td><td class="Toprule" align="left" valign="top">24 (10)</td><td class="Toprule" align="left" valign="top">32 (21)</td><td class="Toprule" align="left" valign="top">23 (11)</td><td class="Rrule" align="left" valign="top">11 (4)</td></tr><tr><td class="Lrule" align="left" valign="top"></td><td align="left" valign="top">600 mg (24 h)</td><td align="left" valign="top">36 (13)</td><td align="left" valign="top">44 (27)</td><td align="left" valign="top">39 (23)</td><td class="Rrule" align="left" valign="top">17 (6)</td></tr><tr><td class="Lrule" align="left" valign="top"></td><td align="left" valign="top">75 mg (Day 5)</td><td align="left" valign="top">12 (6)</td><td align="left" valign="top">13 (7)</td><td align="left" valign="top">12 (5)</td><td class="Rrule" align="left" valign="top">4 (1)</td></tr><tr><td class="Lrule" align="left" valign="top"></td><td align="left" valign="top">150 mg (Day 5)</td><td align="left" valign="top">16 (9)</td><td align="left" valign="top">19 (5)</td><td align="left" valign="top">18 (7)</td><td class="Rrule" align="left" valign="top">7 (2)</td></tr><tr><td class="Lrule" align="left" valign="top">IPA (%)<a class="Sup" href="#footnote-8" name="footnote-reference-8">*</a></td><td align="left" valign="top">300 mg (24 h)</td><td align="left" valign="top">40 (21)</td><td align="left" valign="top">39 (28)</td><td align="left" valign="top">37 (21)</td><td class="Rrule" align="left" valign="top">24 (26)</td></tr><tr><td class="Lrule" align="left" valign="top"></td><td align="left" valign="top">600 mg (24 h)</td><td align="left" valign="top">51 (28)</td><td align="left" valign="top">49 (23)</td><td align="left" valign="top">56 (22)</td><td class="Rrule" align="left" valign="top">32 (25)</td></tr><tr><td class="Lrule" align="left" valign="top"></td><td align="left" valign="top">75 mg (Day 5)</td><td align="left" valign="top">56 (13)</td><td align="left" valign="top">58 (19)</td><td align="left" valign="top">60 (18)</td><td class="Rrule" align="left" valign="top">37 (23)</td></tr><tr><td class="Lrule" align="left" valign="top"></td><td align="left" valign="top">150 mg (Day 5)</td><td align="left" valign="top">68 (18)</td><td align="left" valign="top">73 (9)</td><td align="left" valign="top">74 (14)</td><td class="Rrule" align="left" valign="top">61 (14)</td></tr><tr><td class="Lrule" align="left" valign="top">VASP-PRI (%) <a class="Sup" href="#footnote-9" name="footnote-reference-9">&dagger;</a></td><td align="left" valign="top">300 mg (24 h)</td><td align="left" valign="top">73 (12)</td><td align="left" valign="top">68 (16)</td><td align="left" valign="top">77 (12)</td><td class="Rrule" align="left" valign="top">91 (12)</td></tr><tr><td class="Lrule" align="left" valign="top"></td><td align="left" valign="top">600 mg (24 h)</td><td align="left" valign="top">51 (20)</td><td align="left" valign="top">48 (20)</td><td align="left" valign="top">56 (26)</td><td class="Rrule" align="left" valign="top">85 (14)</td></tr><tr><td class="Lrule" align="left" valign="top"></td><td align="left" valign="top">75 mg (Day 5)</td><td align="left" valign="top">40 (9)</td><td align="left" valign="top">39 (14)</td><td align="left" valign="top">50 (16)</td><td class="Rrule" align="left" valign="top">83 (13)</td></tr><tr class="Last"><td class="Lrule" align="left" valign="top"></td><td align="left" valign="top">150 mg (Day 5)</td><td align="left" valign="top">20 (10)</td><td align="left" valign="top">24 (10)</td><td align="left" valign="top">29 (11)</td><td class="Rrule" align="left" valign="top">61 (18)</td></tr></tbody></table><p>Some published studies suggest that intermediate metabolizers have decreased active metabolite exposure and diminished antiplatelet effects.</p><p>The relationship between CYP2C19 genotype and Plavix treatment outcome was evaluated in retrospective analyses of Plavix-treated subjects in CHARISMA (n=4862) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.</p></div></div><div class="Section" data-sectionCode="43680-8"><a name="i4i_nonclinical_toxicology_id_84e05a35-2336-4bf3-9037-d03a01bef0ac"></a><a name="section-12"></a><p></p><h1><a name="nlm43680-8"></a>13 NONCLINICAL TOXICOLOGY</h1><div class="Section" data-sectionCode="34083-6"><a name="i4i_carcinogenesis_mutagenesis_fertility_id_af9fee8a-b0da-4d2c-8fb9-78baa759f60b"></a><a name="section-12.1"></a><p></p><h2><a name="nlm34083-6"></a>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p class="First">There was no evidence of tumorigenicity when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats at dosages up to 77 mg/kg per day, which afforded plasma exposures &gt;25 times that in humans at the recommended daily dose of 75 mg.</p><p>Clopidogrel was not genotoxic in four <span class="Italics">in vitro</span> tests (Ames test, DNA-repair test in rat hepatocytes, gene mutation assay in Chinese hamster fibroblasts, and metaphase chromosome analysis of human lymphocytes) and in one <span class="Italics">in vivo</span> test (micronucleus test by oral route in mice).</p><p>Clopidogrel was found to have no effect on fertility of male and female rats at oral doses up to 400 mg/kg per day (52 times the recommended human dose on a mg/m<span class="Sup">2</span> basis).</p></div></div><div class="Section" data-sectionCode="34092-7"><a name="i4i_clinical_studies_id_81d09d5e-3ea2-4cf1-96b8-cec5889fad49"></a><a name="section-13"></a><p></p><h1><a name="nlm34092-7"></a>14 CLINICAL STUDIES</h1><p class="First">The clinical evidence of the efficacy of Plavix is derived from three double-blind trials involving 77,599 patients. The CAPRIE study (Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events) was a comparison of Plavix to aspirin. The CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events) and the COMMIT/CCS-2 (Clopidogrel and Metoprolol in Myocardial Infarction Trial / Second Chinese Cardiac Study) studies were comparisons of Plavix to placebo, given in combination with aspirin and other standard therapy. The CHARISMA (Clopidogrel for High Atherothrombotic Risk Ischemic Stabilization, Management, and Avoidance) study (n=15,603) also compared Plavix to placebo, given in combination with aspirin and other standard therapy.</p><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_91a6cb1c-175d-49dd-b4a6-297ce3b606aa"></a><a name="section-13.1"></a><p></p><h2><a name="nlm42229-5"></a>14.1 Acute Coronary Syndrome </h2><p class="First"><span class="Underline"><span class="Italics">CURE</span></span></p><p>The CURE study included 12,562 patients with ACS without ST-elevation (UA or NSTEMI) and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischemia. Patients were required to have either ECG changes compatible with new ischemia (without ST-elevation) or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal. The patient population was largely Caucasian (82%) and included 38% women, and 52% patients &ge;65 years of age.</p><p>Patients were randomized to receive Plavix (300-mg loading dose followed by 75 mg once daily) or placebo, and were treated for up to one year. Patients also received aspirin (75&ndash;325 mg once daily) and other standard therapies such as heparin. The use of GPIIb/IIIa inhibitors was not permitted for three days prior to randomization.</p><p>The number of patients experiencing the primary outcome (CV death, MI, or stroke) was 582 (9.3%) in the Plavix-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%&ndash;28%; p &lt; 0.001) for the Plavix-treated group (see <a href="#id_c0e4b4c3-cb2c-48d2-8e95-8e64bd6db316">Table 4</a>).</p><a name="id_c0e4b4c3-cb2c-48d2-8e95-8e64bd6db316"></a><table><caption><span>Table 4: Outcome Events in the CURE Primary Analysis</span></caption><col align="left" width="31%"><col align="center" width="23%"><col align="center" width="23%"><col align="center" width="23%"><thead><tr class="First Toprule"><td class="Botrule Lrule Rrule" align="left" valign="top">Outcome</td><td class="Botrule Rrule" align="left" valign="top">Plavix<br> (+ aspirin)<a class="Sup" href="#footnote-10" name="footnote-reference-10">*</a></td><td class="Botrule Rrule" align="left" valign="top">Placebo<br> (+ aspirin)<a class="Sup" href="#footnote-10">*</a></td><td class="Botrule Lrule Rrule" align="left" valign="top">Relative Risk<br> Reduction (%)<br> (95% CI)</td></tr><tr class="Botrule Last"><td class="Lrule Rrule" align="left" valign="top"></td><td class="Rrule" align="left" valign="top">(n=6259)</td><td class="Rrule" align="left" valign="top">(n=6303)</td><td class="Rrule" align="left" valign="top"></td></tr></thead><tfoot><tr><td align="left" colspan="4"><dl class="Footnote"><dt><a href="#footnote-reference-10" name="footnote-10">*</a></dt><dd>Other standard therapies were used as appropriate.</dd><dt><a href="#footnote-reference-11" name="footnote-11">&dagger;</a></dt><dd>The individual components do not represent a breakdown of the primary and co-primary outcomes, but rather the total number of subjects experiencing an event during the course of the study.</dd></dl></td></tr></tfoot><tbody><tr class="First Toprule"><td class="Lrule" align="left" valign="top">Primary outcome<br>&nbsp;&nbsp;(Cardiovascular death, MI, stroke)</td><td class="Toprule" align="left" valign="top">582&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9.3%)</td><td class="Toprule" align="left" valign="top">719 (11.4%)</td><td class="Rrule" align="left" valign="top">20%<br> (10.3, 27.9)<br> p &lt; 0.001</td></tr><tr><td class="Lrule" align="left" valign="top">All Individual Outcome Events:<a class="Sup" href="#footnote-11" name="footnote-reference-11">&dagger;</a></td><td align="left" valign="top"></td><td align="left" valign="top"></td><td class="Rrule" align="left" valign="top"></td></tr><tr><td class="Lrule" align="left" valign="top">&nbsp;&nbsp;CV death </td><td align="left" valign="top">318&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5.1%)</td><td align="left" valign="top">345 (5.5%)</td><td class="Rrule" align="left" valign="top">7%<br> (-7.7, 20.6)</td></tr><tr><td class="Lrule" align="left" valign="top">&nbsp;&nbsp;MI</td><td align="left" valign="top">324&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5.2%)</td><td align="left" valign="top">419 (6.6%)</td><td class="Rrule" align="left" valign="top">23%<br> (11.0, 33.4)</td></tr><tr class="Botrule Last"><td class="Lrule" align="left" valign="top">&nbsp;&nbsp;Stroke</td><td align="left" valign="top">75&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1.2%)</td><td align="left" valign="top">87 (1.4%)</td><td class="Rrule" align="left" valign="top">14%<br> (-17.7, 36.6)</td></tr></tbody></table><p>Most of the benefit of Plavix occurred in the first two months, but the difference from placebo was maintained throughout the course of the trial (up to 12 months) (see <a href="#id_dacbfe65-0f82-44a1-ab20-fa06be8cbfa5">Figure 1</a>).</p><a name="nlm34066-1"></a><div class="Warning"><a name="id_dacbfe65-0f82-44a1-ab20-fa06be8cbfa5"></a><a name="section-13.1.1"></a><p></p><p class="First"><span class="Bold">Figure 1: Cardiovascular Death, Myocardial Infarction, and Stroke in the CURE Study </span></p><p><img src="image.cfm?id=34869&type=img&name=1086a7b4%2Db89b%2D4bee%2D8120%2D5f752626c046%2D02.jpg" alt="Figure"></p></div><div class="Section" data-sectionCode="42229-5"><a name="id_53b28a49-333b-4d18-8a7c-c1411e1973e2"></a><a name="section-13.1.1"></a><p></p><p class="First">In CURE, the use of Plavix was associated with a lower incidence of CV death, MI or stroke in patient populations with different characteristics, as shown in Figure 2. The benefits associated with Plavix were independent of the use of other acute and long-term cardiovascular therapies, including heparin/LMWH, intravenous glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors, lipid-lowering drugs, beta-blockers, and ACE-inhibitors. The efficacy of Plavix was observed independently of the dose of aspirin (75&ndash;325 mg once daily). The use of oral anticoagulants, non-study anti-platelet drugs, and chronic NSAIDs was not allowed in CURE.</p></div><a name="nlm34066-1"></a><div class="Warning"><a name="id_f27ddfa3-19ad-4c6e-8de9-d19ace9d529e"></a><a name="section-13.1.2"></a><p></p><p class="First"><span class="Bold">Figure 2: Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study </span></p><p><img src="image.cfm?id=34869&type=img&name=1086a7b4%2Db89b%2D4bee%2D8120%2D5f752626c046%2D03.jpg" alt="Figure"></p></div><div class="Section" data-sectionCode="42229-5"><a name="id_3ba9fef7-cd8e-4f96-8d23-d6395e6ca3d2"></a><a name="section-13.1.2"></a><p></p><p class="First">The use of Plavix in CURE was associated with a decrease in the use of thrombolytic therapy (71 patients [1.1%] in the Plavix group, 126 patients [2.0%] in the placebo group; relative risk reduction of 43%), and GPIIb/IIIa inhibitors (369 patients [5.9%] in the Plavix group, 454 patients [7.2%] in the placebo group, relative risk reduction of 18%). The use of Plavix in CURE did not affect the number of patients treated with CABG or PCI (with or without stenting), (2253 patients [36.0%] in the Plavix group, 2324 patients [36.9%] in the placebo group; relative risk reduction of 4.0%).</p><p><span class="Underline"><span class="Italics">COMMIT</span></span></p><p>In patients with STEMI, the safety and efficacy of Plavix were evaluated in the randomized, placebo-controlled, double-blind study, COMMIT. COMMIT included 45,852 patients presenting within 24 hours of the onset of the symptoms of myocardial infarction with supporting ECG abnormalities (<span class="Italics">i.e.</span>, ST-elevation, ST-depression or left bundle-branch block). Patients were randomized to receive Plavix (75 mg once daily) or placebo, in combination with aspirin (162 mg per day), for 28 days or until hospital discharge, whichever came first.</p><p>The primary endpoints were death from any cause and the first occurrence of re-infarction, stroke or death. </p><p>The patient population included 28% women, 58% age &ge; 60 years (26% age &ge; 70 years), 55% patients who received thrombolytics, 68% who received ACE-inhibitors, and only 3% who underwent PCI.</p><p>As shown in Table 5 and Figures 3 and 4 below, Plavix significantly reduced the relative risk of death from any cause by 7% (p=0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p=0.002).</p><a name="id_e0e17494-b5af-467c-aea3-eb900e92db89"></a><table><caption><span>Table 5: Outcome Events in the COMMIT Analysis</span></caption><col align="center" width="28%"><col align="center" width="18%"><col align="center" width="18%"><col align="center" width="18%"><col align="center" width="18%"><thead><tr class="Botrule First Last"><td class="Lrule Rrule" align="left" valign="top">Event</td><td class="Rrule" align="left" valign="top">Plavix<br> (+ aspirin)<br>(N=22961)</td><td class="Rrule" align="left" valign="top">Placebo<br> (+ aspirin)<br>(N=22891)</td><td class="Rrule" align="left" valign="top">Odds ratio<br>(95% CI)</td><td class="Rrule" align="left" valign="top">p-value</td></tr></thead><tfoot><tr><td align="left" colspan="5"><dl class="Footnote"><dt><a href="#footnote-reference-12" name="footnote-12">*</a></dt><dd>The difference between the composite endpoint and the sum of death+non-fatal MI+non-fatal stroke indicates that 9 patients (2 clopidogrel and 7 placebo) suffered both a non-fatal stroke and a non-fatal MI.</dd><dt><a href="#footnote-reference-13" name="footnote-13">&dagger;</a></dt><dd>Non-fatal MI and non-fatal stroke exclude patients who died (of any cause).</dd></dl></td></tr></tfoot><tbody><tr class="First Toprule"><td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Composite endpoint: Death, MI, or Stroke<a class="Sup" href="#footnote-12" name="footnote-reference-12">*</a></span></td><td class="Rrule" align="left" valign="bottom">2121 (9.2%)</td><td class="Rrule" align="left" valign="bottom">2310 (10.1%)</td><td class="Rrule" align="left" valign="bottom">0.91 (0.86, 0.97)</td><td class="Rrule" align="left" valign="bottom">0.002</td></tr><tr><td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Death</span></td><td class="Rrule" align="left" valign="top">1726 (7.5%)</td><td class="Rrule" align="left" valign="top">1845 (8.1%)</td><td class="Rrule" align="left" valign="top">0.93 (0.87, 0.99)</td><td class="Rrule" align="left" valign="top">0.029</td></tr><tr><td class="Lrule Rrule" align="left" valign="top">Non-fatal MI<a class="Sup" href="#footnote-13" name="footnote-reference-13">&dagger;</a></td><td class="Rrule" align="left" valign="top">270 (1.2%)</td><td class="Rrule" align="left" valign="top">330 (1.4%)</td><td class="Rrule" align="left" valign="top">0.81 (0.69, 0.95)</td><td class="Rrule" align="left" valign="top">0.011</td></tr><tr class="Botrule Last"><td class="Lrule Rrule" align="left" valign="top">Non-fatal Stroke<a class="Sup" href="#footnote-13">&dagger;</a></td><td class="Rrule" align="left" valign="top">127 (0.6%)</td><td class="Rrule" align="left" valign="top">142 (0.6%)</td><td class="Rrule" align="left" valign="top">0.89 (0.70, 1.13)</td><td class="Rrule" align="left" valign="top">0.33</td></tr></tbody></table></div><a name="nlm34066-1"></a><div class="Warning"><a name="id_981352ee-d78e-4246-b352-0f55deb8c45a"></a><a name="section-13.1.3"></a><p></p><p class="First"><span class="Bold">Figure 3: Cumulative Event Rates for Death in the COMMIT Study <a class="Sup" href="#footnote-14" name="footnote-reference-14">1</a></span></p><p><img src="image.cfm?id=34869&type=img&name=1086a7b4%2Db89b%2D4bee%2D8120%2D5f752626c046%2D04.jpg" alt="Figure"></p><hr class="Footnoterule"><dl class="Footnote"><dt><a href="#footnote-reference-14" name="footnote-14">1</a></dt><dd>All treated patients received aspirin.</dd></dl></div><a name="nlm34066-1"></a><div class="Warning"><a name="id_143d12d7-31bb-47d2-813c-7b5bde45bea7"></a><a name="section-13.1.3"></a><p></p><p class="First"><span class="Bold">Figure 4: Cumulative Event Rates for the Combined End point Re-Infarction, Stroke or Death in the COMMIT Study <a class="Sup" href="#footnote-15" name="footnote-reference-15">2</a></span></p><p><img src="image.cfm?id=34869&type=img&name=1086a7b4%2Db89b%2D4bee%2D8120%2D5f752626c046%2D05.jpg" alt="Figure"></p><hr class="Footnoterule"><dl class="Footnote"><dt><a href="#footnote-reference-15" name="footnote-15">2</a></dt><dd>All treated patients received aspirin.</dd></dl></div><div class="Section" data-sectionCode="42229-5"><a name="id_ef95dc89-2c8f-490b-8e50-c6fe88f1ba2e"></a><a name="section-13.1.3"></a><p></p><p class="First">The effect of Plavix did not differ significantly in various pre-specified subgroups as shown in Figure 5. The effect was also similar in non-prespecified subgroups including those based on infarct location, Killip class or prior MI history (see Figure 6). Such subgroup analyses should be interpreted cautiously.</p></div><a name="nlm34066-1"></a><div class="Warning"><a name="id_c931238c-ce07-4838-8483-1a157bce41dd"></a><a name="section-13.1.4"></a><p></p><p class="First"><span class="Bold">Figure 5: Effects of Adding Plavix to Aspirin on the Combined Primary Endpoint across Baseline and Concomitant Medication Subgroups for the COMMIT Study</span></p><p><img src="image.cfm?id=34869&type=img&name=1086a7b4%2Db89b%2D4bee%2D8120%2D5f752626c046%2D06.jpg" alt="Figure"></p><p>* Three similar-sized prognostic index groups were based on absolute risk of primary composite outcome for each patient calculated from baseline prognostic variables (excluding allocated treatments) with a Cox regression model.</p></div><a name="nlm34066-1"></a><div class="Warning"><a name="id_b7dd7226-97ca-4d11-8309-d46cff3f40c1"></a><a name="section-13.1.4"></a><p></p><p class="First"><span class="Bold">Figure 6: Effects of Adding Plavix to Aspirin in the Non-Prespecified Subgroups in the COMMIT Study</span></p><p><img src="image.cfm?id=34869&type=img&name=1086a7b4%2Db89b%2D4bee%2D8120%2D5f752626c046%2D07.jpg" alt="Figure"></p></div></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_a4bf8501-a9f7-43ec-8cb8-76474922346f"></a><a name="section-13.2"></a><p></p><h2><a name="nlm42229-5"></a>14.2 Recent Myocardial Infarction, Recent Stroke, or Established Peripheral Arterial Disease</h2><p class="First"><span class="Underline"><span class="Italics">CAPRIE</span></span></p><p>The CAPRIE trial was a 19,185-patient, 304-center, international, randomized, double-blind, parallel-group study comparing Plavix (75 mg daily) to aspirin (325 mg daily). The patients randomized had: 1) recent histories of myocardial infarction (within 35 days); 2) recent histories of ischemic stroke (within 6 months) with at least a week of residual neurological signs; or 3) established peripheral arterial disease. Patients received randomized treatment for an average of 1.6 years (maximum of 3 years).</p><p>The trial's primary outcome was the time to first occurrence of new ischemic stroke (fatal or not), new myocardial infarction (fatal or not), or other vascular death. Deaths not easily attributable to nonvascular causes were all classified as vascular.</p><a name="id_87d09857-0227-420d-ba21-6be9b336ca94"></a><table><caption><span>Table 6: Outcome Events in the CAPRIE Primary Analysis</span></caption><col align="left" width="40%"><col align="center" width="30%"><col align="center" width="30%"><thead><tr class="First Toprule"><td class="Botrule Rrule" align="left" valign="top"></td><td class="Botrule Rrule" align="left" valign="top"><span class="Underline">Plavix</span></td><td class="Botrule Lrule" align="left" valign="top"><span class="Underline">aspirin</span></td></tr><tr class="Botrule Last"><td class="Rrule" align="left" valign="top">Patients </td><td class="Rrule" align="left" valign="top">n=9599</td><td align="left" valign="top">n=9586</td></tr></thead><tbody><tr class="First Toprule"><td align="left" valign="top">Ischemic stroke (fatal or not) </td><td class="Toprule" align="left" valign="top">438 (4.6%)</td><td align="left" valign="top">461 (4.8%)</td></tr><tr><td align="left" valign="top">MI (fatal or not) </td><td align="left" valign="top">275 (2.9%)</td><td align="left" valign="top">333 (3.5%)</td></tr><tr><td align="left" valign="top">Other vascular death </td><td align="left" valign="top">226 (2.4%)</td><td align="left" valign="top">226 (2.4%)</td></tr><tr class="Botrule Last"><td align="left" valign="top">Total </td><td align="left" valign="top">939 (9.8%)</td><td align="left" valign="top">1020 (10.6%)</td></tr></tbody></table><p>As shown in the table, Plavix was associated with a lower incidence of outcome events, primarily MI. The overall relative risk reduction (9.8% vs. 10.6%) was 8.7%, p=0.045. Similar results were obtained when all-cause mortality and all-cause strokes were counted instead of vascular mortality and ischemic strokes (risk reduction 6.9%). In patients who survived an on-study stroke or myocardial infarction, the incidence of subsequent events was lower in the Plavix group.</p><p>The curves showing the overall event rate are shown in Figure 7. The event curves separated early and continued to diverge over the 3-year follow-up period.</p><a name="nlm34066-1"></a><div class="Warning"><a name="id_cc981258-aee0-43a5-acae-df282763dd40"></a><a name="section-13.2.1"></a><p></p><p class="First"><span class="Bold">Figure 7: Fatal or Non-Fatal Vascular Events in the CAPRIE Study</span></p><p><img src="image.cfm?id=34869&type=img&name=1086a7b4%2Db89b%2D4bee%2D8120%2D5f752626c046%2D08.jpg" alt="Figure"></p></div><div class="Section" data-sectionCode="42229-5"><a name="id_b274e32e-19fa-4dd7-8763-fe0a9f92a3b0"></a><a name="section-13.2.1"></a><p></p><p class="First">The statistical significance favoring Plavix over aspirin was marginal (p=0.045). However, because aspirin is itself effective in reducing cardiovascular events in patients with recent myocardial infarction or stroke, the effect of Plavix is substantial.</p><p>The CAPRIE trial included a population that was randomized on the basis of 3 entry criteria. The efficacy of Plavix relative to aspirin was heterogeneous across these randomized subgroups (p=0.043). It is not clear whether this difference is real or a chance occurrence. Although the CAPRIE trial was not designed to evaluate the relative benefit of Plavix over aspirin in the individual patient subgroups, the benefit appeared to be strongest in patients who were enrolled because of peripheral vascular disease (especially those who also had a history of myocardial infarction) and weaker in stroke patients. In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, Plavix was not numerically superior to aspirin.</p></div></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_9f6c16f1-07a9-4daf-96f5-579f62cadbd3"></a><a name="section-13.3"></a><p></p><h2><a name="nlm42229-5"></a>14.3 Lack of Established Benefit of Plavix plus Aspirin in Patients with Multiple Risk Factors or Established Vascular Disease</h2><p class="First"> CHARISMA </p><p>The CHARISMA trial was a 15,603 subject, randomized, double-blind, parallel group study comparing Plavix (75 mg daily) to placebo for prevention of ischemic events in patients with vascular disease or multiple risk factors for atherosclerosis. All subjects were treated with aspirin 75&ndash;162 mg daily. The mean duration of treatment was 23 months. The study failed to demonstrate a reduction in the occurrence of the primary endpoint, a composite of CV death, MI, or stroke. A total of 534 (6.9%) patients in the Plavix group versus 573 (7.4%) patients in the placebo group experienced a primary outcome event (p=0.22). Bleeding of all severities was more common in the subjects randomized to Plavix.</p></div></div><div class="Section" data-sectionCode="34069-5"><a name="i4i_how_supplied_id_c5968b9f-64e4-4555-b5b5-38eb1de9ba4d"></a><a name="section-14"></a><p></p><h1><a name="nlm34069-5"></a>16 HOW SUPPLIED/STORAGE AND HANDLING</h1><p class="First">Plavix (clopidogrel bisulfate) 75 mg tablets are available as pink, round, biconvex, film-coated tablets debossed with "75" on one side and "1171" on the other. Tablets are provided as follows:</p><dl><dt>&nbsp;</dt><dd> NDC 21695-665-30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bottles of 30</dd><dt>&nbsp;</dt><dd> NDC 21695-665-90&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bottles of 90</dd></dl><div class="Section" data-sectionCode="44425-7"><a name="i4i_storage_id_e6c99e7a-f30b-4440-8bbc-148c1148e6da"></a><a name="section-14.1"></a><p></p><p class="First">Store at 25&deg; C (77&deg; F); excursions permitted to 15&deg;&ndash;30&deg; C (59&deg;&ndash;86&deg; F) [see USP Controlled Room Temperature].</p></div></div><div class="Section" data-sectionCode="34076-0"><a name="i4i_info_patients_id_f1cd3643-003b-457e-bbbf-f44d203fab14"></a><a name="section-15"></a><p></p><h1><a name="nlm34076-0"></a>17 PATIENT COUNSELING INFORMATION</h1><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_6960d9fb-b841-4815-bfc9-1c48dd7fdda6"></a><a name="section-15.1"></a><p></p><h2><a name="nlm42229-5"></a>17.1 Benefits and Risks</h2><ul><li>Summarize the effectiveness features and potential side effects of Plavix.</li><li>Tell patients to take Plavix exactly as prescribed.</li><li>Remind patients not to discontinue Plavix without first discussing it with the physician who prescribed Plavix.</li></ul></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_46f4b661-4777-48c0-a45e-c8f4045f599d"></a><a name="section-15.2"></a><p></p><h2><a name="nlm42229-5"></a>17.2 Bleeding</h2><p class="First">Inform patients that they:</p><ul><li>will bruise and bleed more easily.</li><li>will take longer than usual to stop bleeding.</li><li>should report any unanticipated, prolonged, or excessive bleeding, or blood in their stool or urine.</li></ul></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_b89e98d2-3dd5-461a-9535-d225ace5eba2"></a><a name="section-15.3"></a><p></p><h2><a name="nlm42229-5"></a>17.3 Other Signs and Symptoms Requiring Medical Attention</h2><ul><li>Inform patients that TTP is a rare but serious condition that has been reported with Plavix and other drugs in this class of drugs.</li><li>Instruct patients to get prompt medical attention if they experience any of the following symptoms that cannot otherwise be explained: fever, weakness, extreme skin paleness, purple skin patches, yellowing of the skin or eyes, or neurological changes.</li></ul></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_22f0fe56-9ebb-4197-bc39-527c521e953b"></a><a name="section-15.4"></a><p></p><h2><a name="nlm42229-5"></a>17.4 Invasive Procedures</h2><p class="First">Instruct patients to:</p><ul><li>inform physicians and dentists that they are taking Plavix before any invasive procedure is scheduled.</li><li>tell the doctor performing the invasive procedure to talk to the prescribing health care professional before stopping Plavix.</li></ul></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_7510cadc-9296-49f8-b85a-fa0afaaecdd7"></a><a name="section-15.5"></a><p></p><h2><a name="nlm42229-5"></a>17.5 Concomitant Medications</h2><p class="First">Ask patients to list all prescription medications, over-the-counter medications, or dietary supplements they are taking or plan to take, including prescription or over-the-counter omeprazole, so the physician knows about other treatments that may affect how Plavix works (<span class="Italics">e.g.</span>, warfarin and NSAIDs) <span class="Italics">[see <a href="#i4i_warnings_precautions_id_7dd52f6d-724d-40f4-ba91-92c80743b456">Warnings and Precautions (5)</a>]</span>.</p></div></div><div class="Section" data-sectionCode="42229-5"><a name="i4i_section_id_9e25eb95-0796-4375-95fe-eac1f8246f2b"></a><a name="section-16"></a><p></p><p class="First">Distributed by:<br>Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership<br>Bridgewater, NJ 08807</p><p>Plavix<span class="Sup">&reg;</span> is a registered trademark.</p><p>Repackaged by:</p><p>Rebel Distributors Cor</p><p>Thousand Oaks, CA 91320</p></div><div class="Section" data-sectionCode="51945-4"><a name="i4i_Principal_display_panel_id_63c21185-80d1-459e-bca7-1d0a21fca35c"></a><a name="section-17"></a><p></p><p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 75 mg </span></p><div class="Figure"><img src="image.cfm?id=34869&type=img&name=1086a7b4%2Db89b%2D4bee%2D8120%2D5f752626c046%2D09.jpg" alt="Plavix 75 mg"><p class="MultiMediaCaption"></p></div></div></div><div class="DataElementsTables"><table width="100%" cellPadding="3" cellSpacing="0" class="contentTablePetite"><tbody><tr><td class="contentTableTitle"><strong>PLAVIX&nbsp;							</strong><br><span class="contentTableReg">clopidogrel bisulfate tablet, film coated</span></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%"><tr><td class="formHeadingTitle" colspan="4">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Product Type</td><td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td><td class="formLabel">Item Code (Source)</td><td class="formItem">NDC:21695-665(NDC:63653-1171)</td></tr><tr class="formTableRow"><td class="formLabel" width="30%">Route of Administration</td><td class="formItem">ORAL</td><td class="formLabel" width="30%">DEA Schedule</td><td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;							</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td></tr><tr><td class="formTitle">Ingredient Name</td><td class="formTitle">Basis of Strength</td><td class="formTitle">Strength</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>clopidogrel bisulfate</strong> (clopidogrel) </td><td class="formItem">clopidogrel</td><td class="formItem">75&nbsp;mg</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="2">Inactive Ingredients</td></tr><tr><td class="formTitle">Ingredient Name</td><td class="formTitle">Strength</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>castor oil</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>hydroxypropyl cellulose</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>mannitol</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>cellulose, microcrystalline</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>polyethylene glycol 6000</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>ferric oxide red</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>lactose monohydrate</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>titanium dioxide</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>triacetin</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>carnauba wax</strong></td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="4">Product Characteristics</td></tr><tr class="formTableRowAlt"><td class="formLabel">Color</td><td class="formItem">PINK</td><td class="formLabel">Score</td><td class="formItem">no score</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">ROUND (biconvex) </td><td class="formLabel">Size</td><td class="formItem">9mm</td></tr><tr class="formTableRowAlt"><td class="formLabel">Flavor</td><td class="formItem"></td><td class="formLabel">Imprint Code</td><td class="formItem">                                                      75;1171                        </td></tr><tr class="formTableRow"><td class="formLabel">Contains</td><td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="4">Packaging</td></tr><tr><td class="formTitle" width="1">#</td><td class="formTitle">Item Code</td><td class="formTitle">Package Description</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>1</strong></td><td class="formItem">NDC:21695-665-30</td><td class="formItem">30  in 1 BOTTLE</td></tr><tr class="formTableRow"><td class="formItem"><strong>2</strong></td><td class="formItem">NDC:21695-665-90</td><td class="formItem">90  in 1 BOTTLE</td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td></tr><tr><td class="formTitle">Marketing Category</td><td class="formTitle">Application Number or Monograph Citation</td><td class="formTitle">Marketing Start Date</td><td class="formTitle">Marketing End Date</td></tr><tr class="formTableRowAlt"><td class="formItem">NDA</td><td class="formItem">NDA020839</td><td class="formItem">01/01/1900</td><td class="formItem"></td></tr></table></td></tr></tbody></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Rebel Distributors Corp							(118802834)						</td></tr></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td></tr><tr><td class="formTitle">Name</td><td class="formTitle">Address</td><td class="formTitle">ID/FEI</td><td class="formTitle">Business Operations</td></tr><tr class="formTableRowAlt"><td class="formItem">Rebel Distributors Corp</td><td class="formItem"></td><td class="formItem">118802834</td><td class="formItem">RELABEL, REPACK</td></tr></table></div><p><div class="EffectiveDate">Revised: 12/2010<div class="DocumentMetadata"><div>Document Id: 1086a7b4-b89b-4bee-8120-5f752626c046</div><div>Set id: 1086a7b4-b89b-4bee-8120-5f752626c046</div><div>Version: 1</div><div>Effective Time: 20101228</div></div></div>&nbsp;<div class="DistributorName">Rebel Distributors Corp</div></p></div></div><div id="nlmfooter">	<a href="http://www.nlm.nih.gov">		<img  src="/dailymed/images/logo.gif"		alt="Visit The National Library of Medicine" />	</a>	<a href="http://www.nlm.nih.gov/copyright.html">Copyright</a>,	<a href="http://www.nlm.nih.gov/privacy.html">Privacy</a>,	<a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a><br />	<a href="http://www.nlm.nih.gov">U.S. National Library of Medicine</a>, 8600 Rockville Pike, Bethesda, MD 20894<br />	<a href="http://www.nih.gov/">National Institutes of Health</a>,	<a href="http://www.hhs.gov/">Health &amp; Human Services</a></div></body></html>